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Genetic analysis of Limb Girdle Muscular Dystrophy and Miyoshi Myopathy 
Gillian Summerill 
MSc 2003 
Abstract 
The autosomal recess1ve muscular dystrophies encompass limb girdle muscular 
dystrophy (LGMD) and Miyoshi myopathy (MM), which can show clinical and genetic 
overlap. In this study we have made good progress towards understanding the molecular 
basis of LGMD2I and non-dysferlin MM. 
Our work on LGMD2I involved haplotype analysis of chromosome 19q 13.3 to identify 
potential LGMD2I families. We generated a primary transcript map of the LGMD2I 
region. During this work, mutations in FKRP were described in LGMD2I and MDC I C. 
In 3 of our families showing potential linkage to I9q 13.3, FKRP mutations were 
identified. A common mutation in FKRP, C826A (Leu276IIe), is associated with 
LGMD2I and this mutation was present in 2 of our families and in >70% of the LGMD2I 
families studied. Genotype-phenotype correlations show this mutation is associated with 
a milder disease course. FKRP is a predicted glycosyltransferase and mutations in its 
gene appear to be a common cause of muscular dystrophy. 
Our work on the analysis of non-dysferlin MM supports the existence of a MM gene, 
designated MMD2, on chromosome I Op. We have defined a 25Mb region on 
chromosome 10 shared by affecteds in 2 non-dysferlin MM families. In 5 further 
families, additional haplotype analysis is required to confirm exclusion from 
chromosome 1 Op. 
In the non-dysferlin MM families haplotype analysis of the caveolin 3 region on 
chromosome 3 has suggested no involvement of caveolin 3 in non-dysferlin MM. SSCP 
analysis and sequencing has failed to identify mutation in caveolin 3. 
The confirmation of the MMD2 gene and identification of recombinant boundaries, 
allowing candidate gene analysis, will allow us to identify the MMD2 gene. 
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INTRODUCTION 
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Lll l'HE MUSCULAR DY§l'ROJPIHE§ 
The muscular dystrophies are a group of clinically and genetically heterogeneous 
disorders, characterised by a progressive weakening and wasting of muscles. Since the 
1950's more than 20 types of muscular dystrophy have been categorised. These include: 
o Duchenne/Becker muscular dystrophy (DMD/BMD) 
o Emery-Dreifuss muscular dystrophy (EDMD) 
o Congenital muscular dystrophy (CMD) 
o Limb-girdle muscular dystrophy (LGMD) 
o Facioscapulohumeral muscular dystrophy (FSHD) 
o Myotonic dystrophy (OM) 
There are also many related neuromuscular conditions involving muscles and motor 
nerves. All of the above muscular dystrophies are caused by gene defects which may be 
inherited in an autosomal dominant, autosomal recessive or X-linked manner. Muscular 
dystrophy can also arise by spontaneous mutation. (Emery, AEH., ed. Neuromuscular 
disorders: Clinical and Molecular Genetics (Wiley, 1998) pp. 1-18). 
1.2 DY§TROPIDN & DMDIBMD 
The most common of all the muscular dystrophies affecting children in the UK are 
Duchenne and Becker muscular dystrophies. Molecular genetic evidence showed that 
both disorders segregate with the same Xp21 chromosomal region and that DMD and 
BMD were most likely allelic disorders caused by mutation in the same gene (Kingston et 
12 
al, 1983). Genomic deletions were later detected in region Xp21 for both DMD and 
BMD patients (Kunkel et al, 1985). As inheritance of the disorder is X-linked, patients 
are therefore typically male only. 
The dystrophin gene, which is located at chromosome Xp21, was identified by a 
positional cloning approach (Murray et al., 1982). It is one of the largest genes known, 
with at least 79 exons coding for a cDNA of 14.6 kb which spans over 2.5 Mb of DNA. 
The gene is arranged into four domains: domain A, exons 1-7, actin binding; domain B, 
exons 8-44, rod domain; domain C, exons 45-55, cysteine rich; domain D, exons 56-79, 
C-terminal (Koenig et al., 1988). 
The protein product dystrophin was identified by immunobiochemical and 
immunohistochemical studies (Hoffman et al., 1987), and has been shown to be a 427 
kDa rod shaped spectrin like protein (Koenig et al., 1988). Dystrophin has been localised 
to the sarcolemma (Zubrzycka-Gaam et al., 1988), existing as a complex associated with 
the dystroglycans, syntrophins and sarcoglycans (Campbell and Kahl, 1989; Ervasti and 
Campbell, 1991 ). The protein was found to be absent in DMD patients, and reduced 
and/or altered in BMD patients (Hoffman et al., 1987, 1988; Arahata et al., 1989). Fig. 
1.1 shows the dystrophin-glycoprotein complex and its arrangement at the muscle cell 
membrane. 
The most common dystrophin mutations identified in DMD/BMD are deletions, followed 
by duplications. The resulting frameshift results in a premature termination, causing the 
loss of most of the dystrophin from the muscle cell membrane, which is thought to be 
anchored via its C-terminal 0-domain (Koenig et al., 1988; Ervasti and Campbell, 1991; 
Matsumura and Campbell 1993, 1994). In over 90% of cases this genotype results in the 
13 
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Duchenne phenotype. This runs a much more severe clinical course than the Becker 
phenotype, although the two are clinically indistinguishable. Mutations which are in 
frame but generate a larger or smaller dystrophin molecule do not result in complete loss 
of the protein from the membrane. I 0-40% of the protein is still produced, and this 
results in the milder Becker phenotype. Cases of very short dystrophins have been 
described, leading to mild BMD (Passos-Bueno et al., 1994). These patients usually have 
deletions of exon 45 to 48. 30% of the deletions seen are in exons 2-20, and 70% are in 
exons 44-53. 
Muscle biopsies show a marked variation in muscle fibre size and shape, and alterations 
in fibre type proportions. DMD/BMD patients tend to have a predominance of type I or 
slow twitch fibres and there is a deficiency of type 11 or fast twitch fibres. Becker 
patients have both type I and type 11 fibres. Deposition of connective and adipose tissue 
is seen, along with muscle degeneration and necrosis. 
Onset of DMD and BMD is usually between 3 and 6 years of age. Patients present with 
difficulty in walking or running, may be unable to hop or jump and have difficulty in 
climbing stairs. They may also show difficulty in rising from the floor, and find it 
necessary to use their arms to push themselves up. This characteristic method of standing 
is known as the Gowers sign, and is routinely used as a clinical tool in initially 
diagnosing DMD and BMD. These difficulties are caused by the symmetrical weakness 
of the hip and proximal limb muscles which is seen at onset of the disease. Calf 
hypertrophy may also be a feature, and with progression of the disease muscle weakness 
spreads to the upper limbs and neck. The cardiac and respiratory muscles also become 
involved (Nigro et al., 1990), and mental retardation is seen in a third of Duchenne 
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patients (Bresolin et al., 1994). Loss of ambulation is around the age of 13 years for 
Duchenne boys, and 16 years for Becker. Both disorders are fatal, with death usually 
occurring in the early to mid twenties due to cardiac arrest or respiratory failure. 
1.3 THE LIMB-GIRDLE MUSCULAR DYSTROPHIES 
The limb-girdle muscular dystrophies are a group of clinically and genetically 
heterogeneous progressive muscle disorders. At one time a diagnosis of LGMD would 
be based mainly on exclusion from other forms of muscular dystrophy such as the X-
linked diseases, FSHD or CMD. LGMD at onset can be characterised by weakness of the 
proximal shoulder or pelvic girdle musculature, and may occur at any age. Early 
contractures may be a feature and calf hypertrophy is sometimes evident at onset. 
Progression of the disease varies from mild to severe and muscle involvement is variable. 
LGMD is therefore phenotypically similar to many other forms of muscular dystrophy or 
neuromuscular disorders, such as BMD, manifesting carriers of X-linked muscular 
dystrophies, spinal muscular atrophy and mitochondrial and metabolic myopathies. 
Research into identification of the causative genes for this group of muscular dystrophies 
has led to a greater understanding of the heterogeneity observed within the group and has 
facilitated the possibility of precise molecular diagnoses in many cases. 
To date, 13 types of limb-girdle muscular dystrophy have been characterised, three 
inherited as autosomal dominant and ten as autosomal recessive. These have been 
mapped to many different chromosomes, and in most cases the gene product has been 
identified. Table 1.1 summarises this information, which has served to highlight the 
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~NHERITANCE lOCUS NAME GENE LOCUS GENE PRODUCT Al TERNAT~VE NAME MUTATIONS, TYPE AND DISTR~BIUT!ON 
LGMD1A 5_g_22-24 M_yotilin 
Autosomal LGMD1B 1g_11-21 LaminA/C 
dominant LGMD1C 3p25 Caveolin 3 (CAV3) 
LGMD1 D 7q36.2-36.3 
LGMD2A 15q15.1-21.2 Calpain 3 (CAPN3) Calpainopathy M, small De and SS mutations, described 
Autosomal ' throughout gene. Founder mutations in 
recessive Amish, Reunion, Basque and Turkish pop. 
Occasional recurrent mutations. 
LGMD2B 2p13-16 Dysferlin (DYSF) Dysferlinopathy, Miyoshi Myopathy M, Du, small De, appear to be across gene. 
AQParent founder mutation in Libyan Jews. 
LGMD2G 17_g11-12 Telethonin 
LGMD2H 9_g_31-33 TRIM32? Transition, missense. D487N. 
LGMD21 19q13.3 FKRP C826A common mutation. 
LGMD2D 17q12-21.33 a. -Sarcoglycan a. -Sarcoglycanopathy N, M, Du, small SS mutations. Exon 3 
1 
I (SGCA) I common site. Several recurrent mutations. · 
R77C frequent (-40% of mutations). 
LGMD2E 4q12 f3 -Sarcoglycan f3 -Sarcoglycanopathy M and truncating mutations. M clustered in 
(SGCB) extracellular domain. Founder mutation in I 
1 Amish population (T151R). 
LGMD2C 13q13 y -Sarcoglycan y -Sarcoglycanopathy Small De, few M. Founder mutations in 
(SGCG) · North African (del 521T) and European 
lgypsy population (C283Y). 
LGMD2F 5q33-34 8 -Sarcoglycan 8 -Sarcoglycanopathy ! Single nucleotide substitution or deletions. 
(SGCD) I 
Key to abbreviation of mutations: Nonsense = N, Missense = M, Duplication = Du, Deletion = De, Splice site = SS 
Table 1.1 Types of Limb-Girdle Muscular Dystrophy defined by their genetic basis with causative mutations where known. 
different mechanisms by which muscular dystrophy can arise and has given some insight 
into the observed clinical heterogeneity. 
In light ofthis new information the LGMD phenotypes were reclassified by a consortium 
meeting under the auspices of the European Neuromuscular Centre and a locus-based 
classification was adopted (Bushby and Beckmann, 1995). This meant that conditions 
such as 'severe childhood autosomal recessive muscular dystrophy' (SCARMD), of 
which adult onset cases have been recognised, could be incorporated more accurately into 
the new classification by the loci identified for the group. 
The limb-girdle muscular dystrophies are divided into two groups according to their 
mode of inheritance - autosomal dominant or autosomal recessive. The autosomal 
dominant group was termed LGMD 1, the three forms contained within it mapping to 
three different loci. These loci were designated A, B and C. Similarly, the autosomal 
recessive group was termed LGMD2, with the various loci designated LGMD2A, 
LGMD2B etc. in the order of their identification (Bush by and Beckmann, 1995). 
1.3.1 THE AUTOSOMAL DOMINANT LGMDs 
Only a small proportion of limb girdle muscular dystrophies have dominant inheritance, 
and it is believed that at least some ofthese cases are misdiagnosed and are actually cases 
of the dominantly inherited muscular dystrophy facioscapulohumeral MD (van der Kooi 
et al., 1994), which can present with prominent pelvic girdle weakness and limited facial 
muscle involvement. However it is now possible to diagnose most cases of FSHD by 
18 
DNA analysis, and the three forms of autosomal dominant limb girdle muscular 
dystrophies have been genetically determined. 
An important distinguishing feature between the autosomal dominant LGMD patients and 
the autosomal recessive is the much lower serum creatine kinase levels seen with the 
dominantly inherited forms. 
LGMDlA 
The gene for LGMD lA maps to chromosome 5q22-24, and was identified following a 
study of a large North American pedigree (Gilchrist et al., 1988; Speer et al., 1992). The 
gene product has been identified as myotilin, mutations in which were observed in a large 
North American family of German descent (Hauser et al., 2000), and an Argentinian 
pedigree (Hauser et al., 2002). Myotilin is a sarcomeric protein that binds to alpha-
actinin, filamin c and F-actin, and is localised in the Z-line. The disease association and 
functional characteristics of myotilin suggest a role in stabilisation and anchorage of thin 
filaments, which may be a prerequisite for correct Z-disc organisation. Histologically, 
muscle of affected individuals shows degeneration of myofibres, variations in fibre size, 
fibre splitting, centrally located myonuclei and a large number of autophagic vesicles 
(Fig. 1.2). Affected muscle also shows disorganisation and streaming of the Z-line 
similar to that seen in nemaline myopathy. 
LGMD1A patients present with a predominantly proximal muscular dystrophy, with 
onset ranging from 18 to 35 years, with some suggestion of anticipation (Speer et al., 
1994 ). Progression of the disease is slow with few being confined to a wheelchair. 
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lFig. !.2 lP':raJJgll"®~~~w~ (!}ly~~ll"O!PJ!lnft~ ~bilrm~~ ©if ~ff~d~ §!ken~~an mn!r.!llcie 
HistologicaHy, muscle of affected individuals shows degeneration of myofibres, variations in fibre size (A), centrally located myonuclei (B), 
fibre splitting (C), and a large nwnbe:r of autophagic vesides. 
Symptoms include dysarthia and Achilles tendon contractures, some arm weakness but 
only in association with leg weakness, and distal weakness sometimes becoming a feature 
with progression of the disease. Creatine kinase levels are only mildly elevated. 
JLGMIHB 
Mapping to chromosome 1 q 11-21 (van der Kooi et al., 1997), this form of muscular 
dystrophy presents between 4 and 38 years with proximal lower limb weakness and 
variable calf hypertrophy. The disease is slowly progressive, with Achilles tendon or 
elbow contractures either minimal or becoming a feature late in the course of the disease. 
Creatine kinase levels are normal or mildly elevated. LGMD 1 B is also associated with 
cardiac involvement (van der Kooi et al., 1996), and sudden death is common if the 
condition is untreated. Before the age of 25 most patients have normal atrioventricular 
conduction, but around a third develop first degree heart block between 25 and 35 years. 
This progresses to second degree heart block between 35 and 45 years of age, often 
necessitating the insertion of a pacemaker. Dilated cardiomyopathy may also become a 
feature. This phenotype is similar to one described by Fang and colleagues in 1997 (Fang 
et al., 1997). 
The autosomal dominant Emery-Dreifuss muscular dystrophy also links to the same 
region of chromosome 1 q, the corresponding gene being LMNA which encodes lam ins 
A/C, two proteins of the nuclear envelope that interact directly with emerin. Mutations in 
the LMNA gene have been found to cause at least four different kinds of genetic 
disorders: dilated cardiomyopathy type lA (CMDlA) and familial partial lipodystrophy 
21 
(FPLD), as well as autosomal dominant Emery-Dreifuss muscular dystrophy (AD-
EDMD) and limb-girdle muscular dystrophy type 18 (LGMD1B). 
Sufferers of EDMD show a similar cardiac involvement to those of LGMD I B, although 
the pattern of muscle involvement is dissimilar (Emery, 1989; Rudenskaya et al., 1994). 
This phenotype however is similar to that described in association with secondary p 1 
laminin deficiency (Taylor et al., 1997). LGMD1B and AD-EDMD have been shown to 
be allelic disorders following the identification of mutations in the LMNA gene among 
LGMD1B patients from three families (Muchir et al, 2000). 
However, it has also been noted that a family showing a similar phenotype to that seen in 
LGMD 1 B showed linkage to chromosome 6q23 (Messina et al., 1997). The combination 
of autosomal dominant muscular dystrophy and cardiac disease is therefore genetically 
heterogeneous. 
LGMDlC 
Mapping to chromosome 3p25, the gene product associated with LGMD1C is caveolin 3, 
a muscle specific component of the caveolin membrane with a probable role in signal 
transduction. Caveolin 3 localises to the sarcolemma, and has been shown to associate 
with dystrophin by immunoprecipitation experiments (Song et al., 1996). Caveolin 3 has 
also been shown to co-immunoprecipitate with dysferlin (Matsuda et al, 2001 ), a surface 
membrane protein in skeletal muscle whose deficiency causes distal and proximal, 
recessively inherited, forms of muscular dystrophy Miyoshi myopathy and LGMD2B 
respectively. 
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Heterozygous mutations in the caveolin 3 gene (CA V3) cause different muscle disorders, 
with an R27Q mutation in the CA V3 gene leading to various clinical phenotypes 
including hyperCKemia, rippling muscle disease, distal myopathy and LGMD1C. 
Caveolin 3 labelling has been shown to be reduced in muscle from patients of two 
families with clinical symptoms associated with caveolin 3 mutation, including muscle 
cramps after exercise, calf hypertrophy and mild to moderate proximal muscle weakness. 
Progression of the disease was variable, and creatine kinase concentration was elevated to 
between 4 and 25 times normal. 
1.3.2 THE AUTOSOMAL RECESSIVE LGMDs 
To date, ten subtypes of autosomal recessive limb girdle muscular dystrophies have been 
classified. 
THE SARCOGLYCANOPATHIES 
Four subtypes of LGMD- 2C, 20, 2E and 2F, have been shown to be caused by defects 
in one of the sarcoglycan proteins. The sarcoglycans are a group of transmembrane 
proteins, component members of the dystrophin-glycoprotein complex of the muscle cell 
membrane, along with dystroglycan and the syntrophins (Fig 1.3). 
The dystroglycans span the sarcolemma, interacting with dystrophin inside the 
sarcolemma and laminin in the extracellular matrix, while the syntrophins are located 
intracellularly. The sarcoglycans themselves are of unknown function (Worton, 1995; 
Straub and Campbell, 1997; Ozawa et al., 1998), but because of their association with 
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forms of muscular dystrophy it is apparent that these proteins play a pivotal role in the 
maintenance of muscle membrane integrity. They all share a similar structure, having a 
small intracellular domain which may be located at either the C- or N-terminus, and a 
single transmembrane domain. The extracellular domain is large and contains potential 
N-glycosylation signals (Ozawa et al., 1998). Expression of two of the sarcoglycans is 
limited to striated muscle, whilst others are more widely expressed. 
Five sarcoglycan proteins have been characterised to date- a-sarcoglycan, [3-sarcoglycan, 
y-sarcoglycan, 8-sarcoglycan and E-sarcoglycan. The recently identified E-sarcoglycan 
shares similarity with a-sarcoglycan and has been mapped to chromosome 7q21 
(McNally et al., 1998b ), but unlike the other sarcoglycans has not yet been implicated in 
the causation of muscle disorders. 
The individual sarcoglycan proteins appear to associate together as a distinct subcomplex 
(Yoshida et al., 1994; Vainzof et al., 1996; Iwata et al., 1996; Inoue et al., 1996; Cullen 
et al., 1996; McNally et al., 1998b). Loss of one component ofthe sarcoglycan complex 
is often associated with a secondary reduction in the expression of the others although 
this may not always be the case, particularly if the primary loss is of a- or y-sarcoglycan 
(Vainzof et al., 1996; Jones et al., 1998; Ozawa et al., 1998). Loss of [3- or 8-sarcoglycan 
does however seem to be more often associated with a reduction in the expression of all 
the proteins in the sarcoglycan complex (Bonnemann et al., 1996; Vainzof et al., 1996). 
A diagnosis of sarcoglycanopathy may be made by clinical examination, protein and 
molecular analyses, and DNA studies. Onset of the disease may be in the pelvic or 
shoulder girdle muscle groups, or both simultaneously. Onset of weakness in any distal, 
facial or extraocular muscles would tend to exclude a diagnosis of sarcoglycanopathy. 
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Calf hypertrophy is frequent but not always a feature, and there may be considerable 
intrafamilial variability. Onset of the disease may be at any age, though onset beyond the 
early twenties is less common. Progression ofthe disease may be very fast or very slow, 
and cardiac involvement is be reported in a minority of cases. If a family history is 
available, it may be possible to distinguish whether the condition is dominantly or 
recessively inherited - dominant inheritance would be an exclusion criterion for a 
sarcoglycanopathy, which are all recessively inherited. Serum creatine kinase is elevated, 
and investigations such as muscle biopsy may show dystrophic changes. Any 
abnormality of dystrophin would normally be an exclusion criterion, but because of the 
tight association of the proteins of the dystrophin-glycoprotein complex it is now 
accepted that dystrophin analysis may not always be completely normal in cases of 
sarcoglycanopathy (Vainzof et al., 1996; Jones et al., 1998). The finding of muscle 
biopsy features diagnostic of a neuropathic process, inflammatory changes, metabolic or 
mitochondrial abnormalities also exclude the diagnosis. Testing of muscle biopsies with 
antibodies to the sarcoglycan proteins can give an indication of the level of expression. 
This has become the primary diagnostic tool for this group of diseases (Anderson, 1996; 
Sewry et al., 1996). All four sarcoglycan antibodies should be used in order to identify 
which protein is causing the primary defect. This protein is usually completely absent 
while the others may be reduced, although in some sarcoglycanopathies a loss of all of 
the sarcoglycan proteins may be seen. Multiplex Western Blotting can also be useful 
(Anderson and Davison, 1999). This technique allows for comparison of the relative 
abundance of each sarcoglycan from a single muscle sample. From these analyses the 
candidate sarcoglycan gene or genes may be identified. In families containing more than 
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one affected or unaffected sib, haplotype analysis may be performed to aid in 
identification of the mutated sarcoglycan, and mutation screening performed using SSCP 
techniques or DNA sequencing. 
The sarcoglycans are thought to maintain the structural integrity of the muscle fibre 
membrane, and primary defects in one of the a-, [3-, y-, or o-sarcoglycans have now been 
implicated as the cause of one of the four sarcoglycanopathies (Roberds et al., 1994; 
Noguchi et al., 1995; Lim et al., 1995; Bonnemann et al., 1995; Nigro et al., 1996). 
a-SARCOGLYCANOPATHY 
Also known as LGMD2D, a-sarcoglycanopathy was previously known as 50 DAG, 
adhalin, A2 and SCARMD2. The protein involved in the disease is a-sarcoglycan, the 
gene mapping to chromosome 17q 12-21.33. The gene was identified after purification of 
a-sarcoglycan, a50kDa dystrophin associated glycoprotein (50 DAG). Cloning of the 
gene was possible after antibodies generated to 50 DAG were used to screen an 
expression skeletal muscle library. Expression of the a-sarcoglycan mRNA has been 
shown to be within striated muscle only (Quinlivan et al., 1997). a-sarcoglycan has three 
domains - a large N-termina1 glycosylated extracellular domain, a single C-terminal 
transmembrane domain and a short C-terminal intracellular domain. In LGMD2D 
patients a-sarcoglycan is completely absent, and many different causative mutations have 
been identified across the 10 exons ofthe gene, which code for a cDNA of 1.474kb with 
an ORF of 1.161 kb. These mutations include nonsense, splice site, missense and 
duplications, with missense mutations being the most commonly seen. Recurrent 
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mutations have been documented. Exon 3, which encodes part of the extracellular 
domain is the site most frequently showing mutations, accounting for 46% of affected 
chromosomes. The most frequent mutation seen is a R77C, seen on 40% of mutated 
chromosomes. More than 70% of patients presenting with a-sarcoglycanopathy are 
compound heterozygotes, with cases of this form of LGMD having been reported 
worldwide. 
a-sarcoglycanopathy has a variable age of onset ranging from 3-15 years, mean 8.5 
years. Adult onset cases, although uncommon, have been reported, including an 
asymptomatic patient aged 36 years (Fanin et al., 1997). Patients typically present with 
difficulty running and climbing stairs, some reporting muscle cramps on exercising. Toe 
walking can be an early feature, along with mild calf hypertrophy but occasionally 
involving other muscle groups. Scapular winging is often seen at presentation, although 
weakness tends to be in the lower limbs initially. Femoral muscles tend to be less 
involved than those of the pelvic group, with quadriceps and hamstrings usually showing 
equal involvement. Early distal lower limb involvement, if present, tends to be in the 
anterior tibial group. Early involvement of the deltoid is sometimes seen, with weakness 
of the biceps but relative preservation of the triceps. Creatine kinase levels in patients 
tend to be normal, or increased to the upper limit of normal. Presymptomatic elevation of 
creatine kinase has been reported, although is not reliable in determining carrier status. 
This selectivity of muscle involvement tends to remain as the disease progresses, but 
eventually all muscle groups become involved apart from facial, ocular and 
velopharyngeal. Cardiomyopathy has been reported in some cases, and respiratory 
complications mean that ventilatory assistance is required. Scoliosis and contractures 
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may develop with progression of the disease, but no mental retardation is seen. 
Progression tends to be faster with earlier age of onset, patients often being confined to a 
wheelchair by the age of 15. However there is much variability, even intrafamiliarly, and 
some sufferers may continue to walk independently late into adult life. 
(3-SARCOGL YCANOPATHY 
Previously known as A3b, (3-saroglycanopathy has been reclassified as LGMD2E. The f3 
subunit of the sarcoglycan complex is a 43 kDa protein also known as 43 DAG. The 
protein has three domains - a large C-terminal extracellular domain, with a single 
transmembrane domain and a small N-terminal intracellular domain. Expression is 
ubiquitous. Purification of the dystrophin-glycoprotein complex led to identification of 
the gene, whose 6 exons code for a cDNA of approx 1 kb, mapping to chromosome 4q 12. 
Causative mutations have been identified as missense and truncating mutations. The 
missense mutations occur in exon 3 which codes for the immediate extracellular domain, 
and results in a very severe phenotype. A founder mutation has been identified in the 
Am ish population (T 151 R), which results in a much milder phenotype. The contrast in 
the severity of the phenotypes suggests that the missense mutations may be occurring in a 
region of exon 3 which is particularly sensitive to their effect on the secondary structure 
of the protein. 
Patients presenting with (3-saroglycanopathy are deficient for the protein and may also 
display an absence or deficiency of the other sarcoglycans. Deficiency of P- and 
similarly 8-sarcoglycan seem often to be associated with a total deficiency of the 
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complex (Bonnemann et al., 1996; Vainzof et al., 1996). This can be detected by 
analysis of a muscle biopsy using specific antibodies to the various sarcoglycans. 
Immunostaining may also suggest which protein is primarily involved. Dystrophin levels 
may also be reduced but the protein is not absent, and serum creatine kinase levels are 
elevated. 
This form of LGMD presents with an extremely broad range of severity, also showing 
intrafamilial variability. Amongst the Am ish families studied by Lim et al ( 1995), all 
showing the same homozygous missense mutation, variability was such that with a mean 
age of onset of 7.6 years, the age at loss of ambulation ranged from 12 to 38 years 
(mean, 26 years). A very severe disease may occur in J3-saroglycanopathy (Bonnemann 
et al., 1995, 1996), with patients presenting in early childhood being confined to a 
wheelchair by their early teens. In contrast an Amish family heterozygous for two 
missense mutations presented with symptoms in adult life, and retained independent 
ambulation into the sixth decade (Duclos et al., 1998). 
As with a.-sarcoglycanopathy the limb and pelvic muscles are affected and there is 
involvement of the scapular muscles. Calf hypertrophy is also seen. Cardiac 
involvement and respiratory complications occur with some patients only, and sufferers 
display normal intellect. 
y-SARCOGLYCANOPATHY 
y-sarcoglycanopathy, or LGMD2C, was previously termed 35 DAG, A4 and SCARMDl. 
It is caused by defect in the y subunit of the sarcoglycan complex, which is a 35 kDa 
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protein having three domains - a long extracellular carboxy terminus, and single 
transmembrane domain and a short amino terminal cytoplasmic domain. The protein is 
expressed ubiquitously, and its small gene of 292 amino acids and 8 exons maps to 
chromosome 3q 13. In cases of clinically proven y-sarcoglycanopathy, the y-sarcoglycan 
protein is completely absent from muscle biopsies. This is accompanied by a reduction 
or a complete absence of a- and ~-sarcoglycan, though dystrophin levels are unaffected. 
Serum creatine kinase levels are elevated. 
Causative mutations are generally in the extracellular domain, and are either missense or 
more often small deletions. Founder mutations have been identified in two populations-
a ~521-T mutation in patients of North African and Arab origin, and a C283Y mutation 
in the European gypsy population. 
Clinical symptoms are again similar to those of the other sarcoglycanopathies - calf 
hypertrophy, proximal lower limb weakness with toe walking a feature, generally no 
cardiac or respiratory problems and normal intelligence. Again there is much phenotypic 
variability, from Duchenne-like with childhood onset and loss of independent ambulation 
at 16-17 years, to a milder form with late onset. This variability is seen both inter- and 
intra-familiarly. 
o-SARCOGLYCANOPATHY 
8-sarcoglycanopathy, or LGMD2F has causative mutations is the o-sarcoglycan protein. 
As with the other sarcoglycans, the protein has three domains - a large extracellular 
domain, and single transmembrane and a short intracellular domain. Its gene, mapping to 
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chromosome 5q33-34, has 9 exons and five mutations have been reported to date. A 
missense mutation E262K is present amongst Caucasians, and a founder mutation, 
~656C in exon 7, is present in four African-Brazilian families. This deletion results in 
the production of a truncated protein which causes primary deficiency of 8-sarcoglycan in 
muscle tissue, and disruption of the whole sarcoglycan complex. In all cases of 8-
sarcoglycanopathy an absence of a-, P- and 8-sarcoglycan is seen, accompanied by an 
absence or reduction ofy-sarcoglycan. There is also a reduction of dystrophin. 
The gene for 8-sarcoglycan was identified in the Syrian cardiomyopathic hamster by 
candidate gene analysis. The hamster has a mutation in 8-sarcoglycan and may manifest 
either a dilated or a hypertrophic cardiomyopathy, though the skeletal muscles are not 
prominently involved (Sakamoto et al., 1997; Nigro et al., 1997). Muscle from the 
hamster showed a defiency of a-sarcoglycan, but this was shown to be a secondary 
reduction from RNA analysis and mapping studies. No mutations were found in the P- or 
y-sarcoglycan genes, but mutations were identified in the 8-sarcoglycan gene. On muscle 
biopsy all the sarcoglycan proteins were shown to be absent, and dystrophin was present 
but a-dystroglycan was absent or greatly reduced. The dystroglycan complex was seen 
to be completely disassociated from the sarcoglycan complex in the muscle cell 
membrane. 
Families with LGMD2F showed linkage to the human region where the Syrian hamster 
gene causing cardiomyopathy had been mapped. These patients may potentially be at 
risk of cardiac complications. 
Few cases of genetically proven LGMD2F have been documented so far, but those 
reported show a very severe clinical course (Nigro et al., 1996b; Duggan et al., 1997b ). 
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Age of onset ranges from 4 to I 0 years, with loss of independent ambulation at 9-16 
years and death occurring at 9-19 years, usually due to respiratory failure. Patients show 
normal intelligence, and although muscular dystrophy is not a prominent clinical feature, 
muscle degeneration has been confirmed histologically. 
LGMD2A 
Also known as calpain-deficient LGMD or calpainopathy, this form of LGMD is caused 
by mutations in the CAPN3 gene, which maps to chromosome 15ql5.1-21.2. More than 
100 pathogenic mutations have been identified to date, which are found across the entire 
gene as missense or nonsense substitutions, small deletions or small insertions. 
The gene product, calpain 3, is a muscle specific 94-k.Da calcium-activated neutral 
protease 3, playing indispensable roles in various cellular functions such as signal 
transduction, cell growth and differentiation, apoptosis and necrosis. The loss of its 
function leads to activation of other proteases. Calpain has also been shown to bind to 
titin in myofibrils (Sorimachi et al., 1995), and regulates levels of IKBa, a complex 
involved in cell survival. 
Although most of the detailed physiological functions of calpains have not yet been 
elucidated, their importance is apparent from the increasing number of papers reporting 
relationships between the malfunction of calpain and diseases such as Alzheimer's, type 
2 diabetes and cataracts, as well as muscular dystrophies. 
The gene responsible for LGMD2A was first localised to chromosome 15 in a population 
on the island of La Reunion. This highly isolated population, apparently descended from 
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a smaller founder population, showed a surprising heterogeneity of mutations of the 
CAPN3 gene. This was termed the 'Reunion paradox' (van Ommen, 1995; Richard et 
al., 1995), and it was possible to identify six disease-associated haplotypes and 
subsequently mutations. In contrast, calpainopathy in other populations shows only a few 
recurrent mutations, one appearing to be conserved with a founder haplotype in families 
from such diverse geographical origins as America, Brazil and Reunion (Richard et al., 
1997). Common mutations have also been described in Turkey and the Basque region of 
Spain (Topaloglu et al., 1997; Dincer et al., 1997; Urtasun et al., 1998). 
Calpainopathy patients show normal dystrophin and sarcoglycan expression m their 
muscle tissue, but serum creatine kinase can be elevated to greater than 10 times normal. 
Muscle tissue shows evidence of apoptosis, and apoptotic myonuclei are present. Initial 
studies showed that calpain 3 was undetectable in normal muscle, but RNA levels were 
high. This led to the suggestion that the protein had a very short half-life (Sorimachi et 
al., 1993). Subsequent studies have shown that calpain 3 is detectable in skeletal muscle 
(Spencer et al., 1997), and a monoclonal antibody has recently been generated to calpain 
3 which can be used for immunoblotting of muscle samples (Anderson et al., 1998). This 
provides a more straightforward starting point for diagnosis than mutation detection, 
given the heterogeneity of the mutations seen in this large gene. 
Calpainopathy patients show a predominantly symmetrical and atrophic muscle 
involvement, with prominent calves seen only in a minority. Contractures of the Achilles 
tendon may be an early feature, and contractures elsewhere, including the spine, may also 
be seen (C. Pollitt et al., unpublished observations). Pelvic girdle weakness is evident at 
onset, but often with sparing of the hip abductors which may persist even with 
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progression of the disease, giving patients a characteristic stance. Abdominal muscles 
tend to be lax, and scapular winging is a common feature at onset. This symptom may be 
so severe that a diagnosis of scapulohumeral muscular dystrophy may be considered. 
Patients often present with difficulty running or climbing stairs, and may have frequent 
falls. The age at onset is in the majority of cases between 8 and 15 years, though a range 
from 2 to 40 years has been reported (Richard et al., 1997). The rate of progression 
varies, but intrafamilial variation is less marked than that which is seen with the 
sarcoglycanopathies. The disease is not usually as severe as other forms of LGMD, with 
confinement to a wheelchair usually necessary 11-28 years after the onset of symptoms. 
Respiratory muscles may become involved and complications can be severe, but 
involvement of cardiac muscles has not been reported. 
In patients who are homozygous for a mutation, genotype-phenotype correlations have 
been possible. As a general rule, those with homozygous null mutations tend to have the 
most severe clinical course. 
LGMD2B 
Dysferlin deficient LGMD, or dysferlinopathy, is confirmed by the demonstration of 
mutations in the dysferlin gene, or through linkage to chromosome 2p 13, to which the 
gene maps, in large families. The dysferlin gene encodes a novel protein which shares 
homology with the Caenorhabditis-elegans sperm vesicle fusion protein FER-1 
(Achanzar, W. E. and Ward, S., 1997). Although the function of the dysferlin protein is 
unknown, it has been shown to be a membrane protein (Moss et al., 1999; Matsuda et al., 
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1999) which is characterised by the presence of tandem C2 domains and is predicted to 
have a role in membrane trafficking (Liu et al., 1998; Bashir et al., 1998). A possible 
association between dysferlin and caveolin-3 has recently been described (Matsuda et al., 
2001). Caveolin-3 is a skeletal muscle membrane protein important in the formation of 
caveolae, mutations in which cause LGMDlC. Dysferlin has been shown to co-
immunoprecipitate with caveolin-3 in normal human skeletal muscle, suggesting the 
hypothesis that one function of dysferlin may be to interact with caveolin-3 to subserve 
signalling functions of caveolae (Matsuda et al., 2001 ). 
The gene for the early adult onset distal myopathy known as Miyoshi myopathy has also 
been shown to be localised to the same genetic interval on chromosome 2 as LGMD2B 
(Bejaoui et al., 1995). Families linked to chromosome 2p 13 with different members 
affected by variable phenotypes have been reported (Weiler et al., 1996; Illarioshkin et 
al., 1996). Mutations in the dysferlin gene have now been identified, and it has been 
shown that patients from the same family who are affected by the same homozygous 
mutation may present with either a limb-girdle or a Miyoshi pattern of muscle disorder 
(Liu et al., 1998; Bashir et al., 1998). It is unclear at present why dysferlin mutations 
should produce such phenotypic variability, but one theory which has been put forward is 
the existence of modifier genes of dysferlin (Anderson et al., 1999; McNally et al., 2000) 
The dysferlin gene is large, having around 55 exons, and mutations appear to be across 
the gene (Liu et al., 1998; Bashir et al., 1998). Few have been described to date but they 
include missense, small deletions and duplication, with a founder mutation apparent in 
the Libyan Jewish population. 
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LGMD2B patients typically present between the ages of 15-30 years after having had 
normal mobility in childhood. Common early symptoms include an inability to walk on 
tiptoe and calf atrophy. Calf hypertrophy may be present in a minority of patients early 
in the course of the disease, but this is only a transient feature (Bashir et al., 1998). Early 
contractures are rare, and scapular involvement, although not present at onset, can be a 
mild feature with progression of the disease. The first detectable muscle weakness is 
often the pelvifemoral muscles, while muscle CT scanning may also show asymptomatic 
involvement of the gastrocnemius muscles - thus the inability to walk on tiptoe. The 
anterior distal leg muscles and the distal arm muscles tend to be spared, even with 
progression of the disease. Dystrophin, sarcoglycan and calpain 3 analyses tend to be 
normal, but creatine kinase levels are usually markedly elevated at presentation, often 20-
150 times normal (Mahjneh et al., 1996). 
In contrast, Miyoshi myopathy is a predominantly distal muscular dystrophy with early 
involvement of the posterior lower limb muscles. As with LGMD2B, there is early 
involvement of the gastrocnemius muscles causing an inability to stand on tiptoes, and 
proximal lower and upper limb weakness often develops with progression of the disease. 
There is also a characteristic elevation of serum creatine kinase levels to 10-1 00 times 
normal. Having been previously described mainly in Japan (Linssen et al., 1997), 
Miyoshi myopathy is now increasingly being recognised in the West, and it is becoming 
apparent that not all cases of Miyoshi myopathy map to the dysferlin gene. At least two 
additional Miyoshi myopathy loci have been highlighted, and a second locus has been 
tentatively assigned to chromosome 10 (Linssen et al., 1998). 
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LGMD2G 
This form of autosomal recessive muscular dystrophy has been linked to chromosome 
17q11-12. Linkage to this locus was established through the study of many large LGMD 
families failing to show linkage to any of the other LGMD loci (Moreira et al., 1997). 
Causative mutations occur in the telethonin gene, whose protein product is a 19kDa 
sarcomeric protein localised to the Z-disc of skeletal and cardiac muscles. Telethonin has 
been found to be one of the substrates of the serine kinase domain of titin, and has been 
shown to play a role in myofibril assembly. 
LGMD2G patients tend to present in their early twenties with difficulty climbing stairs 
and running, and foot-drop may be noted as an early feature. Proximal and distal lower 
limb weakness is apparent at onset, with weakness of the proximal upper limb 
musculature. Loss of independent ambulation is often around 18 years after onset. 
Muscle biopsy examination reveals normal sarcoglycan staining, but creatine kinase 
levels may be elevated to between 3 and 17 times normal. Histopathological studies 
reveal a large number of rimmed vacuoles, which are not a common feature of the 
autosomal recessive LGMD's. Muscle of patients with telethonin mutation displays a 
similar level of Z-disc disorganisation as that seen in patients with mutation in myotilin. 
LGMD2H 
LGMD2H was first described in 1976, as a mild autosomal recessive myopathy affecting 
a population of Hutterites in Manitoba (Shokeir and Kobrinsky, 1976; Weiler et al., 
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1998). The causative gene for the disease was mapped to a 6.5 Mb region m 
chromosomal region 9q31-33. Recent research has narrowed the candidate region to a 
560 kb region on chromosome 9 containing at least four genes. Mutation screening was 
carried out and the gene TRIM32, coding for a member of the tripartite-motif (TRIM) 
family of proteins, was identified as the most likely gene for LGMD2H. All of the 
affected individuals in the study were found to be homozygous for the mutation, which 
replaces aspartate with asparagine at position 487, but none of the control subjects were 
found to have the mutation (Wrogemann et al., 2002). Although the function ofTRIM32 
is unknown, current knowledge of the characteristic domains of this family of proteins 
suggest that it may be an E3-ubiquitin ligase (Joazeiro and Weissman 2000), with a 
function in the Ub-proteosome pathway in which proteins are assigned for degradation. 
This represents a novel pathogenic mechanism for muscular dystrophy. 
Sufferers of LGMD2H have a variable clinical presentation (Shokeir and Kobrinsky 
1976; Weiler et al., 1997; Bushby 1999b). Onset is usually between the ages of 8 and 27 
years, and progression of the disease is slow. Affected individuals present with proximal 
lower limb weakness and an elevated serum creatine kinase level (2-30 times normal). 
With progression of the disease, the proximal upper limb muscles become involved, 
predominantly the trapezius and deltoid. Mild distallimb involvement may also be seen, 
with weakness of the brachioradialis and anterior peroneal muscles. Most patients 
remain ambulatory into the sixth decade of life. 
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LGMD21 
This form of LGMD was originally described in a large consanguineous Tunisian family 
(Driss et al., 2000), where linkage to chromosome 19q 13.3 was reported. This LGMD 
locus is identical to that of a congenital muscular dystrophy, MDC 1 C, suggesting that the 
underlying pathology of these diseases follow a similar pathway. The congenital 
muscular dystrophies are autosomal recessive disorders distinguishable by their age of 
onset which is usually within the first six months of life, with hypotonia and a dystrophic 
muscle biopsy. Like the limb-girdle muscular dystrophies they are highly heterogeneous. 
MDC 1 C is a severe form characterised by early onset, inability to achieve independent 
ambulation, muscle hypertrophy, marked elevation of serum creatine kinase, no brain 
involvement and a secondary deficiency of lam in in a2 (Mercuri et al., 2001 ). a-
dystroglycan expression is also abnormal. The LGMD21 form is characterised by a high 
variability in clinical course, with phenotypes ranging from Duchenne-like disease course 
including cardiomyopathy to milder phenotypes with a slow progression. Secondary 
deficiencies of a-dystroglycan and a2-laminin are also a feature. 
The causative mutation is in the fukutin-related protein gene (FKRP), which shares 
sequence similarities with a family of proteins involved in the glycosylation of cell 
surface molecules (Brockington et al., 2001 b). Part of our work has been in this area, and 
has led to the identification of mutations in the same gene amongst affected individuals 
from 17 LGMD21 families. LGMD21 has therefore been shown to be a milder allelic 
variant of congenital muscular dystrophy MDC 1 C. 
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The most common mutation in FKRP, which encodes a putative glycosyltransferase, is 
C826A (Leu276Ile). If homozygous this results in a clinically less severe LGMD2I 
phenotype, but if heterozygous the disease runs a much more severe clinical course. A 
missense mutation in the FKRP gene results in an MDC 1 C phenotype, suggesting that the 
C826A change is a less disruptive FKRP mutation. 
MDC&LGMD21 
Congenital muscular dystrophy is an autosomal recessive muscular dystrophy with early 
onset (Voit, 1998). Sufferers show generalised hypotonia, with contractures and joint 
deformities, and histologically, patient muscle shows dystrophic changes as well as white 
matter changes in the brain. There are several forms of congenital muscular dystrophy, 
including MDClA, MDC1B and MDC1C. These disorders also share clinical features 
with three other myopathies, Fukuyama congenital muscular dystrophy (FCMD), muscle-
eye-brain disease (MEB) and Walker-Warburg syndrome (Emery, AEH., ed. 
Neuromuscular disorders: Clinical and Molecular Genetics (Wiley, 1998) pp. 21-48). 
The congenital muscular dystrophies are divided into two groups, merosin-deficient 
CMD and merosin-positive CMD. Mutation in the merosin gene causes complete loss of 
the protein, resulting in a severe muscular dystrophy phenotype (Voit, 1998). Sufferers 
show severe neo-natal hypotonia and delayed motor development. Atrophy and 
weakness of muscles are a feature, as well as respiratory problems. Serum creatine 
kinase levels are shown to be elevated, and examination of the brain shows changes in 
white matter. In contrast, with non-merosin linked CMD the presence of the protein 
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merosin results in a milder clinical course (Voit, 1998). Patients still show the same 
symptoms of neo-natal hypotonia, delayed motor development, muscle atrophy and 
weakness and respiratory problems along with elevated creatine kinase levels, but there 
are no changes in the white matter of the brain. Not all merosin deficient CMD are due 
to mutations in the merosin gene, suggesting that merosin deficiency is a secondary 
feature. MDCIC shows merosin deficiency but maps to chromosome 19ql3.3 and is due 
to mutation in the FKRP gene (Brockington et al., 2001b). 
Merosin (a.-laminin) is a muscle specific laminin, existing in the extracellular domain 
where it forms a major component of the basement membrane (Emery, AEH., ed. 
Neuromuscular disorders: Clinical and Molecular Genetics (Wiley, 1998) pp. 21-48). 
Three different laminin chains, a, J3 and y, exist together in different combinations to 
form up to 11 laminin isoforms, of which the a.2 chain is involved in the muscle cell 
membrane. This chain links with a receptor on the a.-dystroglycan component of the 
dystrophin-glycoprotein complex (Emery, AEH., ed. Neuromuscular disorders: Clinical 
and Molecular Genetics (Wiley, 1998) pp. 21-48). 
Congenital muscular dystrophy type lA, mapped to chromosome 6q22-23, is due to 
mutations in the LAMA2 gene causing deficiency of merosin (Hebling-Leclerc et al., 
1995). Other CMD genes include the fukutin related protein gene FKRP, encoding a 
protein which, as suggested by its name, is related to fukutin. FKRP is also a putative 
glycosyltransferase. Mutations in the FKRP gene cause both limb-girdle muscular 
dystrophy type 21 (LGMD21), and congenital muscular dystrophy type I C (MDC 1 C) 
(Brockington et al., 200la). The mutation C826A (Leu276Ile) in the FKRP gene is the 
most common mutation found in any autosomal recessive muscular dystrophy in the UK 
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(Brockington et al., 200 I a). If present homozygously, the mutation results in a milder 
LGMD2I phenotype, but if inherited heterozygously the disease runs a much more severe 
clinical course. Missense mutations in the FKRP gene are associated with the MDC I C 
phenotype, but no null mutations are observed in these patients, suggesting that these 
mutations are embryonic lethal. 
The fukutin and fukutin-related protein genes encoding putative glycosyltransferases are 
involved in the glycosylation of dystroglycan (Martin-Rendon and Blake, 2003). a-
Dystroglycan is a receptor for laminin and this has been shown by analysis of patient 
muscle by Western blotting using a-dystroglycan antibodies. If not glycosylated 
correctly, dystroglycan fails to bind laminin, altering the stability and architecture of the 
muscle cell. LGMD21 and MDC I C patients both show abnormal glycosylation of a-
dystroglycan (Martin-Rendon and Blake, 2003). In these studies a-dystroglycan is 
absent or reduced and shows altered mobility of SDS gels. 
Protein glycosylation occurs in the endoplasmic reticulum and the Golgi apparatus. 
Proteins with roles in cell-cell adhesion have been shown to be heavily glycosylated. 
Proteins can be grouped into N-glycans and 0-glycans depending upon the amino acid 
residue which is glycosylated (Martin-Rendon and Blake, 2003). 0-glycosylation 
involves serine and threonine residues, N-glycosylation involving asparagine residues 
(Paulson, I989). The different sugars are added to proteins and they impact on the 
structure and function of the protein (Breton and Imberty, 1999). 0-mannose linked 
glycosylation is high in the brain, peripheral nerve and muscle tissue, with 30% of 0-
linked sugar chains in the brain being 0-mannose (Van den Steen, et al., 1998). a-
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Dystroglycan is an 0-mannose linked protein, which goes some way towards explaining 
the occurrence of white matter changes in the brains of CMD patients. 
1.4 MULTIPLE MECHANISMS CAUSING MUSCULAR DYSTROPHY 
The mappmg of the muscular dystrophies to so many chromosomes, and the 
identification of multiple causative mutations has served to highlight the different 
mechanisms by which muscular dystrophy can arise, with three distinct mechanisms now 
emergmg. 
1.4.1 DYSTROPHIN/GL YCOPROTEIN COMPLEX 
The dystrophin/glycoprotein complex forms a bridge across the muscle membrane, 
between the inner cytoskeleton (dystrophin) and the basal lamina (merosin). It is thought 
to provide structural integrity to the muscle cell membrane, protecting muscle fibres from 
long term contraction-induced damage and necrosis. 
Mutations causing loss of most of the dystrophin from the muscle cell membrane usually 
result in the Duchenne phenotype of muscular dystrophy. Mutations generating a larger 
or smaller dystrophin molecule but not resulting in its complete loss usually result in the 
milder Becker phenotype. 
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1.4.2 TITIN/SARCOMERIC PROTEINS 
Titin is a giant muscle protein (363 exons), stretching from the Z disc to the M line. It 
provides muscle elasticity and acts as a docking bay for the sarcomeric proteins involved 
in muscle contraction. Four muscular dystrophies have been linked to defects in these 
proteins: LGMD1A, mapping to chromosome 5q and showing mutation in the gene 
product myotilin; LGMD2A, mapping to chromosome 15q with defects in the protein 
calpain 3; LGMD2G, mapping to chromosome 17q and showing mutation in the 
sarcomeric protein telethonin; and TMD, mapping to chromosome 2q with defects in the 
protein titin. 
1.4.3 ABNORMAL GL YCOSYLA TION 
Abnormal glycosylation of a-dystroglycan or laminin a2 is seen in many muscular 
dystrophies including MDC1C, FCMD, MEB, Wa1ker-Warburg and also LGMD2I, in 
which patients show reduction or deficiency of a-dystroglycan. a2-laminin is a 
constituent of the basal lamina which links to dystroglycan and which provides structural 
support in the extracellular matrix. Mutations in genes with glucosyltransferase activity 
have been identified as responsible for these diseases, suggesting that abnormal 
processing of a-dystroglycan may be central to the pathogenesis of a significant number 
of genetic conditions (Muntoni et al., 2002). 
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L5 AllM§ 
The aims of this study were two-fold. 
L To perform genetic analysis of the ILGMD2K region on chromosome 19q13.3. 
a) In a collection of 6 unclassified LGMD families, haplotypes of chromosome 19q 13.3 
were generated to identify potential LGMD21 families. 
b) In parallel the genome databases were screened to assemble a physical and a transcipt 
map ofthe LGMD21 region. 
c) From this map candidate genes were identified for mutation screening. 
2. To perform genetic ananysis of non-dysferlin Miyoshn myopathy. 
a) In 2 large non-dysferlin MM families haplotypes of chromosome 1 Op were generated. 
Recombinant and non-recombinant regions were identified and compared between 
affecteds in the two families. This data, together with the evidence of tentative linkage to 
chromosome 1 Op in these families was used to determine the existence of the MMD2 
gene. 
b) In 7 additional non-dysferlin MM families haplotypes for chromosome 10 and 
chromosome 3, to which caveolin 3 maps, were generated, to provide insight into the 
genetic heterogeneity of non-dysferlin MM and the role of caveolin 3 in non-dysferlin 
MM. 
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CHAPTER2 
MATERIALS AND METHODS 
46 
Unless specified otherwise, all inorganic chemicals were purchased from Merck, BDH 
Laboratory Supplies, Poole, BH 15 1 TO, England. 
2.1 FAMILY INFORMATION 
Genomic DNA from fifteen clinically assessed families were used, after ethical consent 
was given for their use in this study by the local MREC and Durham University ethical 
committee. 
2.1.1 PATIENT DNA SAMPLES 
In order to preserve anonymity, the samples were assigned a code upon receipt for use 
during this study. The families themselves were numbered from one to fifteen, and 
individual members of the family were assigned P for a parent or C for a child. If more 
than one child was present in the family, then Cl denotes the first child, C2 the second 
and so on. M or F then indicates whether the individual is male or female, and finally A 
denotes an individual affected by muscular dystrophy and U an individual unaffected. 
Thus 5-C3/F A is the third child of family 5, who is a female affected by muscular 
dystrophy. In the case of Family 15, DNA from four further related family members was 
introduced. These individuals were assigned R for relative. This information is 
summarised in Table 2.1. Pedigrees for the fifteen families are shown in the Appendix. 
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Table 2.1 DNA Samples 
Family Family Stock Tube Stock cone. New 
Number Member Reference ng/ul Reference 
1 Parent, male 236 300 1-P/MU 
Parent, female 237 200 1-P/FU 
Child, female 238 200 1-C1/FA 
Child, male 235 300 1-C2/MA 
2 Parent, female 25 200 2-P/FU 
Parent, male 24 <10 2-P/MU 
Child, male 26 200 2-C1/MA 
Child, female 27 200 2-C2/FA 
Child, female 29 50 2-C3/FU 
3 Parent, female 7-167 200 3-P/FU 
Child, male 7-169 200 3-C1/MU 
Child, male 7-170 150 3-C2/MU 
Child, male 7-171 200 3-C3/MA 
Child, female 7-172 300 3-C4/FA 
4 Parent, male 1.1569 300 4-P/MU 
Child, male 1.157 300 4-C1/MU 
Child, male 1.1571 300 4-C2/MU 
Child, female 1.1524 100 4-C3/FA 
Child, male 1.1716 250 4-C4/MU 
Child, male 1.1651 250 4-CS/MU 
Child, male 1.1715 300 4-C6/MU 
Child, female 1.1717 250 4-C7/FU 
Child, female 1.1523 400 4-C8/FA 
Child, male 1.1718 150 4-C9/MU 
5 Parent, male 5.632 400 5-P/MU 
Child, male 5.634 400 5-C1/MU 
Child, female 5.633 400 5-C2/FU 
Child, female 10.197 400 5-C3/FA 
Child, male 5.568 400 5-C4/MA 
6 Parent, male 5.144 400 6-P/MU 
Parent, female 5.143 400 6-P/FU 
Child, female 5.142 400 6-C1/FA 
Child, female 5.141 400 6-C2/FA 
7 Child, male A 2000 7-C1/MU 
Child, female B 2000 7-C2/FU 
Child, female c 2000 7-C3/FU 
Child, female D 200 7-C4/FU 
Child, female E 2000 7-CS/FU 
Child, male F 2000 7-C6/MU 
Child, male G 2000 7-C7/MA 
Child, female H 2000 7-C8/FA 
8 Child, female I 200 8-C1/FU 
Child, female J 1000 8-C2/FU 
Child, female K 1000 8-C3/FU 
Child, female L 1000 8-C4/FU 
Child, male M 1000 8-CS/MU 
Child, female N 1000 8-C6/FA 
Child, male 0 1000 8-C7/MA 
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Family Family Stock Tube Stock cone. New 
Number Member Reference ng/ul Reference 
9 Parent, male 5.4701 200 9-P/MU 
Parent, female 5.47 200 9-P/FU 
Child, female 5.4681 200 9-C1/FU 
Child, female 5.4682 200 9-C2/FA 
10 Parent, female 1.1193 200 10-P/FU 
Child, male 1.11928 200 10-C1/MU 
Child, male 5.56 200 10-C2/MA 
Child, male 1.11929 200 10-C3/MU 
11 Parent, male 5.1383 200 11-P/MU 
Parent, female 5.138 200 11-P/FU 
Child, female 5.1379 200 11-C1/FU 
Child, female 5.1382 200 11-C2/FU 
Child, female 5.136 200 11-C3/FA 
Child, male 5.1384 200 11-C4/MU 
Child, male 5.1405 200 11-C5/MU 
Child, male 5.1381 200 11-C6/MU 
Child, male 5.1361 200 11-C?/MA 
12 Parent, female 5.2397 200 12-P/FU 
Child, male 5.2396 200 12-C1/MU 
Child, male 5.2395 200 12-C2/MU 
Child, male 5.2180 200 12-C3/MA 
13 Parent, male 5.4211 200 13-P/MU 
Parent, female 5.4153 200 13-P/FU 
Child, female 5.4258 200 13-C1/FU 
Child, male 5.4154 200 13-C2/MA 
Child, female 5.4242 200 13-C3/FU 
Child, female 5.4243 200 13-C4/FU 
Child, female 5.4155 200 13-C5/FA 
14 Parent, male 5.373 200 14-P/MU 
Parent, female 5.3376 200 14-P/FU 
Child, female 5.3552 200 14-C1/FU 
Child, female 5.3465 200 14-C2/FU 
Child, female 5.3375 200 14-C3/FA 
15 Child, male 8 10000 15-C6/MA 
Child, male 9 10000 15-C4/MA 
Parent, male 10 10000 15-P/MU 
Parent, female 11 10000 15-P/FU 
Relative, male 12 10000 15-R1/MU 
Relative, female 13 10000 15-R2/FU 
Relative, female 14 10000 15-R3/FU 
Relative, male 15 10000 15-R4/MU 
Child, female 16 10000 15-C1/FU 
Child, male 17 10000 15-C2/MU 
Child, female 18 10000 15-C3/FU 
Child, female 19 10000 15-C5/FU 
49 
2.2 AGAROSE GEL ELECTROPHORESIS 
DNA was electrophoresed on horizontal slab minigels (50-75ml volume) ranging m 
concentration from 0.8-1.5% (w/v) (0.8-1.5% agarose (BMA), 10% 1 OX TAE buffer, 
0.5jlg/ml ethidium bromide (Sigma)). Electrophoresis was performed in IX TAE buffer 
(40mM Tris, lmM EDTA, pH 7.7) containing 0.2jlg/ml ethidium bromide, at lOOV for 
10-40 minutes. The DNA within the gel was visualised under long wave ultraviolet light 
using a Gel Doe 1000 transilluminator (BIO RAD). 
Genomic DNA was quantified by loading ljll of DNA combined with 9jll of loading 
buffer (31.25% glycerol, lOmM Tris pH8.0, O.OIM EDTA pH8.0, lmg/ml Fast Orange G 
(Sigma)), against a 200ng and lOOng standard (pGEM® 3Zf(+), Applied Biosystems). 
An estimation of the concentration of each sample was recorded (see Table 2.1 ), and the 
stock DNA samples were then diluted to a working concentration of 1 OOpmolljll. 
PCR reactions for genotyping were prepared for electrophoresis by adding 5jll of sample 
to 5jll of loading buffer. Samples were run against 5jll of GeneRuler™ 1 OObp DNA 
Ladder (MBI Fermentas), facilitating the identification and quantification of the required 
PCR bands. An example is shown in Fig. 2.1. 
PCR reactions for SSCP analysis were prepared as above for genotyping, and quantified 
by comparison to 5jll ofGeneRuler™ lOObp DNA Ladder (MBI Fermentas). 
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Fig. 2.1 Agarose gel containing completed PCR reactions run against lOObp ladder. 
PCR products were generated using microsatellite marker DlOS570. The required reaction 
product, 287-305bp, was identified by comparison to the lOObp ladder in lane 1. 
500bp .... 
400bp -----l ... ~
300bp ... 
200bp----. 
1 OObp -----. 
2 3 4 
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2.3 MICRO§A l'ELLITE ANAL Y§I§ 
The LGMD21 locus maps to chromosome 19q13.3. Genetic data suggests that the 
mutated gene lies between the microsatellite markers D 19S606 and D I9S879 (Driss et al, 
2000). Microsatellite markers mapping within this region were analysed in families I-6. 
Chromosome I9 markers are described in Table 2.2. 
A second locus for Miyoshi Myopathy (MM) has been tentatively assigned to 
chromosome I Op (Linssen et al., 1998). Families 7 -I5 were analysed initially using 
chromosome 10 markers identified by Linssen and colleagues, then informative families 
were analysed further using markers mapping distally and proximally to this region. 
Chromosome I 0 markers are described in Table 2.2. 
Primers used for genotyping were labelled at the 5' end with a fluorescent dye, either 6-
FAM, NED or HEX (NED- Applied Biosystems, 6-FAM, HEX- Therrmo Hybaid, 
MWG-Biotech, Invitrogen). Details of the primer sequences and PCR product sizes are 
given in table 2.2. 
PCR amplification of microsatellite loci under standard conditions was performed in 25!11 
volumes in PCR buffer (10% IOX buffer (supplied with Taq enzyme (Promega))) 
containing 2.5mM each dNTP in the presence of 1.5mM MgCI2. One unit ofTaq enzyme 
(Promega) was used for DNA synthesis. Genomic DNA was present at a concentration 
of IOOpmoll!ll with forward and reverse oligonucleotides at 20!-lM. 
PCR conditions employed were: denaturation at 94°C for 4 min followed by 30 cycles of 
denaturation at 94°C for 30 sec, annealing at 50°C for 1 min, extension at 72°C for I min. 
Reactions were carried out on a DNA thermal cycler (Perkin Elmer). 
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Vl 
w 
Marker Forward primer sequence 5' ---. 3' 
0195596 GAA TCC GAG AGG TGG G 
0195902 CCA TCC T AA TGA GGG CAA 
0195606 AGG GCT GGG ACC TCA C 
0195879 CTG AGT GTG AA T GAG GCA AC 
01051745 CCC ACA TGG CAG GAT TC 
01051713 GAC AGC AAC T AA CCT CCT GTA AG 
0105591 ACC TCG AAG GTC TGT TCT CC 
0105553 AAG GTT ACT GAG AAG ACA GTT TTC A 
01052194 CAA TTT GGA AAA CTT TTA TCA ATC A 
01051674 AAC AGA AGT CAA ATC AA T GAA C 
01051768 AGA AGC CGT GTC TGC C 
01051666 CAT GGA CCC ATC GGT G 
0105191 CTT T AA TTG CCC TGT CTT C 
0105547 CTT GAA AGG CGG AGG C 
0105570 GCA TTC ATC CAA CAA GCA TA 
01052325 CTC ACG AAA GAA GCC TTC TG 
01051734 GCC TGG GTG ACA GAG TGA GAT TCT A 
0353611 GCT ACC TCT GCT GAG CAT 
0353691 TCT CAG CAA TAG CAA ACA TCA GG 
0351307 T AA ATG ACA CTC CAG CAG CA 
0351270 TGG AAC TGT ATC AAA GGC TC 
--
Table 2.2 Microsatellite Markers 
Reverse primer sequence 5' ---. 3' Modification PCR product size (bp) 
GCC AGA GCC ACT GTG T 5': 6-FAM 213-221 
GCA CCA GTG ACT GCC TGT 5': NEO 199-217 
CCA ACA CAC TGT CTG CCT T 5': 6-FAM 172-190 
AGG CCA GAG GAC TGA TTG 5': HEX 217-265 
ATA ACC CAT AAT AGC CAA GAT ACG G 5': 6-FAM 149-175 
TGT GTT ATT CAA GGG TCA GC 5': 6-FAM 245-255 
GGC TTT ATG GAT CAT ATT AAT CCA C 5': HEX 212-232 
GGG TGC TAG TCC AGA CAT TT 5': 6-FAM 205-235 
TTT GAG ATG GGT CTT ACA ATT GG 5': NEO 226-227 
ACT AGA GGC GCC CAC C 5': 6-FAM 163-193 
CCC AGG GAC TTA GGG TG 5': HEX 163-181 
GCT GGT CTC AAA CCT CCC 5': 6-FAM 218-277 
TTA ATT CGA CCA CTT CCC 5': 6-FAM 124-152 
CCC AA T AGT CCA CAG GGA G 5': 6-FAM 235-250 
AAT TAG TTC CAT GGG CAC AG 5': 6-FAM 287-305 
GAG CTG AGA GAT CAC GCA CT 5': 6-FAM 119-154 
ACA CAC GTA CACATG GGG TGG T 5': 6-FAM 163-189 
TAG CAA GAC TGT TGG GG 5': 6-FAM 107-137 
TTG AAA CCA GGG TGA CAA ATA CAT C 5': 6-FAM 214-260 
GCA CTC ATC AAT GTA TGG GG 5': HEX 237-251 
TTG CAT TAG AGC TAT TCT CCA GA 
-
&': 6-FAM 164-186 
In some cases the standard PCR conditions produced many non-specific products (Fig. 
2.2), or the yield of the required product was very low. If the non-specific products were 
of a similar size to the required product, then the PCR reaction was repeated under 
optimised conditions in order to reduce the generation of the non-specific products which 
interfere with accurate sizing of alleles during genotyping. Optimisation was also carried 
out to improve yield of the required product where necessary. This involved varying the 
concentration of MgCI2 between 1.5mM and 2.5mM, and the concentration of the 
primers between 15 J.tM and 25 J.tM. In some cases it was also necessary to vary the 
annealing temperature between 50°C and 55°C. Fig. 2.3 shows PCR products generated 
after optimisation was carried out to reduce the generation of non-specific products. 
2.4 GENOTYPING 
Genotyping was carried out on an ABI Prism 377XL DNA Sequencer. Data is collected 
by automated fluorescence detection using the software Data Collection v2.5 (Applied 
Biosystems). Using this system, DNA fragments can be labelled with up to three 
different coloured fluorescent dyes, a fourth dye colour is reserved for labelling an 
internal size standard. By electrophoresing the size standard simultaneously with each 
individual sample, precise size calling is performed without the problems of band-shift 
artifacts or run-to-run variation. The software GeneScan® Analysis v3.1 (Applied 
Biosystems) analyses the data collected to accurately size DNA fragment molecular 
lengths based on their normalised mobilities. The software uses the size standard to 
create a sizing curve for each lane, then determines the length of each dye-labelled PCR 
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Fig. 2.2 Agarose gel containing completed PCR reactions showing 
non-specific extension products 
The samples in lanes 2, 3 and 4 show many non-specific extension products 
and smearing. The required product, indicated below, is of a low concentration 
compared to the non-specific products. 
Required_____. 
product 
1 2 
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3 4 
Fig. 2.3 Agarose gel containing completed PCR reactions after optimisation. 
PCR products were generated using microsatellite marker D 1 OS 191. The required 
product, 124-152bp, is indentifiable by comparison to the 1 OObp ladder in lane 1 
and the generation of non-specific reaction products has been eliminated. 
200bp __. 
100bp __. 
I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
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product by comparing it with the sizing curve for the specific lane in which it was 
electrophoresed. This allows resolution of up to 1 base pair, which is necessary for the 
analysis ofmicrosatellites or short tandem repeats (STRs). 
For genotyping, PCR amplified DNA was used at a concentration of 1 0-20ng/~l. This 
was combined with GeneScan™ 500 ROX™ Size Standard (Applied Biosystems) in 
loading buffer (0.2-0.4~1 labelled PCR product, 0.125~1 ROX, 1.5~1 loading buffer 
(deionised formamide containing 10% Blue dextran/EDTA (Applied Biosystems))). 
Because each of the fluorescent dyes used (6-F AM, NED, HEX) has a different 
absorption maximum, the intensity of fluorescent signal emitted differs for each dye. 
Therefore in order to generate signals of equal intensity for each dye during data 
collection, it was necessary to load greater amounts of PCR products labelled with low 
signal intensity emission dyes, compared to those with high signal intensity emission 
dyes. Hence the amount of labelled PCR product loaded onto the gel varied from 0.2-
0.4~1. 
It was possible to multiplex samples into a single lane by using either colour or fragment 
length to distinguish between the fragments. Hence PCR products of similar lengths 
were electrophoresed simultaneously in one lane provided the primers were labelled with 
different colours, and products with the same fluorescent labels could be combined if 
their product lengths were different. These considerations formed the criteria for 
selection of fluorescent labels for each individual marker used. When multiplexing was 
carried out, the appropriate volume of each PCR product was pooled and then combined 
with 0.125~1 ofROX and 1.5~1 of loading buffer. 
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Samples were electrophoresed on a 4% denaturing polyacrylamide 36cm WTR slab gel 
(6M urea, 4.5% acrylamide/bis-acrylamide, 29:1 ratio, 10% 1 OX TBE, 0.05% ammonium 
persulfate, 0.05% TEMED) in IX TBE buffer (0.09M Tris, 0.09M orthoboric acid, 2mM 
EDT A), using a 50-lane square tooth comb. Electrophoresis was carried out at 3kV for 3 
hours, using virtual filter set D. These parameters were selected in order to achieve high 
resolution (up to 1 bp) rather than high speed analysis. 
The collected data was analysed initially using GeneScan® Analysis v3.1 (Applied 
Biosystems). The files were then imported into Genotyper® v2.5 (Applied Biosystems) 
for further analysis, where the detected peaks were sized. Fig 2.4 shows an example of a 
Genotyper® file. 
2.5 BIOINFORMATICS 
2.5.1 MOLECUALR ANALYSIS OF CHROMOSOME 19 
LGMD21 was mapped to 19q 13.3 by Driss et al, (2000). The microsatellite markers 
described in this paper were used in this study to determine whether the haplotypes of 
families 1-6 were consistent with linkage. The primer sequences of these markers were 
found by accessing the UniSTS database, through the NCBI (National Center for 
Biotechnology Information) website, whose home page ts at 
http://www.ncbi.nlm.nih.gov. The UniSTS database is a NCBI resource that reports 
information about markers, or Sequence Tagged Sites (STS). Marker and mapping data is 
integrated from public resources including GenBank, RHdb, GOB and various human 
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Fig. 2.4 Genotyper® file 
Genotyper® file showing PCR products generated using the microsatellite marker 
DlOS2325. Accurate sizes in base pairs are given in boxes below each peak. This 
file shows five alleles in one family studied- 118bp, 128bp, 144bp, 150bp and 
155bp. 
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3000 
2000 
1000 
and mouse maps. Information about primer sequences, product size, and mapping 
information can be obtained, and links to other databases are available. Fig. 2.5 shows a 
UniSTS entry for the microsatellite marker D19S596. 
The Entrez database was screened in order to locate the genomic contigs with which each 
of the microsatellite markers are associated. Entrez is a text-based search and retrieval 
system which covers all the major databases at NCBI, including PubMed, Nucleotide and 
Protein Sequences, Protein Structures, Complete Genomes, Taxonomy, OMIM, and 
others. Entrez is accessible at http://www. ncbi.nih.gov/Entrez/. The database BLAST 
(Basic Local Alignment Search Tool) was also screened independently to confirm the 
data. BLAST provides a method for rapid searching of nucleotide and protein databases, 
and is accessible at http://www.ncbi.nlm.nih.gov/BLAST/. Fig 2.6 shows the result of an 
Entrez search for the microsatellite marker D 19S596. The first entry shows the contig 
address, NT_011109. 
The NCBI Map Viewer was used to find gene information by position relative to other 
landmarks. Map Viewer presents genetic information for many genomes, and the 
availability of whole genome sequences means that objects such as genes, markers, 
clones, sites of variation and clone boundaries can be positioned by aligning defining 
sequence from these objects against the whole genomic sequence. This position 
information can then be compared to information from other genetic or physical 
mapping. Using this resource, the order of the markers and their contig assignment was 
established. By zooming in on the map it was possible to obtain Gene Sequence 
information (provisional gene order). Fig 2.7 shows a fully detailed view within Map 
Viewer, showing the gene FLJ 10922 and its position on the contig NT _ 011109. 
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Fig. 2.5 UniSTS 
Results of search for microsatellite marker D 19S596, showing forward and 
reverse primer sequences and PCR product size. 
GenBank Accession: 
I Homo sap_ie_n_s_~ 
D19S596 
AGGGCTGGGACCTCAC 
CCAACACACTGTCTGCCTT 
172-190 (bp), Homo sapiens 
253152 
UniSTS:15315 
Also D19S606, 253152, 8030WE1, AFMa133zh9, AFMb030we1, stSG34742, 
known as: RH74437, RH84008, RH86248, W6232, HSB030WE1, SHGC-21097 
Cross References 
rs2245418 
RH74437 
RH84008 
RH84008 
RH86248 
RH86248 
GDB:378151 
lng Information 
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Summary 
Oenebridge4 
Oenebridge4 
StanfordG3 
Genebridge4 
Stanford TNG 
Fig. 2.6 Entrez Nucleotide 
Results of Entrez Nucleotide search for D 19S596. The first entry shows the contig address 
NT 011109. 
Homo sapiens chromosome 19 genomic contig 
gil29800.'594!re~NT _011109.1.'51Hs19 _11266(29800.'594] 
H.sapiens (D19S.'596) DNA segment containing(CA) repeat; clone AFMa133zh9; single read, sequence tagged site 
gil1233.'519jembiZ.'52219.11HSA133ZH9(1233.'519] 
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f 
Fig. 2. 7 Map Viewer 
Map viewer resource within Entrez Genome, showing a section of the contig NT_011109 and its 
respective genes. 
Homo sapiens Map View Build 34 Version 1 BLAST The HUJIWl Genome 
Chromosome: l:l:l~l!!Z~2.1QllllU~Ul!!lZ~ ( 19)~ll:l:l~Y 
Query: D19S596 ~ 
lli"!a..ster ap: Ge es On eqY!ill_ce 
Total Genes On Chromosome: 1512 
Ma JS & 0 Jlions 
Region Displayed: S3,131K-S3,851Kbp Download/View Seauence/Evidence 
Genes Labeled: 20 Total Genes in Region: 24 
Conti~~:.:tl~ Genes_seq~ Symbol Q !d!:!!IQill g Cyto 
CABP5 t OMIM J!.Yll!ill~l!l!!lh!n C 19q13.33 
PLA2G4C t QM!MJ!.Yll!ill~l!l!!lhrn C 19q13.3 
Description 
calciwn binding protein 5 
phospholipase A2, group IVC (cytosolic, calcium-independent) 
t QMIMJ!.Y9Ililfimmhm C 19q132-q13.3ligasel,DNA,ATP-dependent 
11119+ 
t 
MOC17986+ 
FU32926 t 
EMP3 • 
FUI0922 t 
KDELRI t 
QElli1Q • 
GRWD • 
KCNJ14 • 
PSCD2 • 
c 19q13.33 
c 19q13.33 
!YI:ltilln:mmhrn c 19ql3.33 
OMIM!YJ:ltill~l!l!!lh!n 
J!.Yll!ill~l!l!!lhrn 
OMIM !Y 1l! ill~ mm hm 
c 
c 
c 
19q13.3 
19q13.33 
19q13.3 
tumor up-regulated CARD-containing antagonist of caspase nine 
hypothetical protein MOC17986 
hypothetical protein FU32926 
epithelial membrane protein 3 
hypothetical protein FUI0922 
KDEL (Lys-Asp-Giu-Leu) endoplasmic reticulum protein retention 
QMlM l!.Y 91 lil n: mm bm c 19ql3.1-qter glutamate recaptor, ionot.ropic, N-methyl D-aspartate 2D 
J!.Y912lfil!l!!lhm c 
QM!M J!.Y 1l! ill fi mm brn c 
QMlM J!.Y 1l! ill~ l!l!!l brn c 
19q13.33 
19q13 
19q13.3 
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glutamate rich WD repeat protein GRWD 
potassium inwardly-rectifying channe~ subfamily J, member 14 
pleckst.rin homology, Sec7 and coiled-coil domains 2 ( cytohesin-2) 
In order to identify candidate genes for analysis, the resource LocusLink was used. 
LocusLink organizes information from collaborating public databases and from other 
groups within NCBI to provide a locus-centred view of genomic information. Each 
LocusLink entry contains a collection of links to provide more information about a locus. 
The resource is accessible at http://www.ncbi.nlm.nih.gov/LocusLink/, or can be 
accessed by clicking on the genes of interest displayed within the contigs in Map Viewer. 
Fig. 2.8 shows a LocusLink entry for the gene FLJl 0922. Each of the genes were 
screened in LocusLink, and their entries in UniGene and OMIM were also viewed. 
UniGene partitions GenBank sequences into a non-redundant set of gene-oriented 
clusters, each of which contains sequences that represent a unique gene, as well as related 
information such as the tissue types in which the gene has been expressed and map 
location. This resource can be accessed via LocusLink, or directly at 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene. Fig. 2.9 shows the UniGene 
entry for the gene FLJ10922. OMIM (Online Mendelian Inheritance in Man) is a 
directory of human genes and genetic disorders. It too is accessible via LocusLink, or 
directly at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM. OMIM provides 
text overviews of genetic disorders and gene loci, and provides connections to other data 
resources such as bibliographic, sequence and map information. Entries may also include 
clinical features, inheritance, population genetics, heterogeneity and mapping 
information. With reference to LocusLink, UniGene and OMIM a profile was built for 
each gene, including mapping data, characterization, expression information and any 
published information available. From this data it was possible to identify candidate 
genes for mutation screening. 
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Fig. 2.8 LocusLink 
Results of Locus Link search for the gene FLJ 10922 showing the hypothetical 
protein product FLJ10922 with unknown function. 
Preiein: 
Sui5mit GenelUF 
gene with prouin pro duct, function unknown 
hypothetical protein FU10922 
19 
19q13.33 
Chr. 19 
NM 018273 
Re!Seq 
RH102358 
GenBank Source: 
NP 060743 hypotheticalproteinFU10922 
~ 
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mv 
mv 
BL 
Fig. 2.9 UniGene 
Results of UniGene search for the hypothetical protein FLJ 10922, the product of the 
gene FLJI 0922 identified on contig NT _ 0 Ill 09. The entry details the expression of 
the protein in skeletal muscle. 
UniGene 
FLJ10922: Hypothetical protein FLJ10922 
UNKS: Locuslink I HomoloGene 
SELECTID MODEL ORGANISMPROTFJN SIMILARITIES 
organism, protein and percent identity and length of aligned region 
Hsapiens ref:NP 060743 1 - 100 % /128 aa 
hypothetical protein FLJ10922 (see ProtEST) 
[Homo sapiens] 
M musculus: ref:NP 056549 1 - 32 %/127 aa 
procollagen, type V, alpha 1; (see ProtEST) 
pro-alpha1(V) collagen [Mus 
musculus] 
19 
Genome View: Chromosome 19 
UniSTS entries: stSG53674 Map View 
UniSTS entries: RHI02358 Map View 
cDNA sources: 2 pooled turners (clear cell type); adenocarcinoma; brain; 
lliUlJtli1:1Lt=ly•lU.Cl'"t"It=rJ.U.11&.t::U t::JUJUUlt:l.litll t1l1t:UUI,;W:I..1J.I.UIUU,.) }JUU!t::IJ 
tumors; NEUROBlASTOMA COT 25-NORMAUZED; cervical 
carcinoma cell line ; myeloid cells, 18 pooled CML cases, 
BCRIABL rearrangement positive, includes both chronic phase 
and myeloid blast crisis ; placenta; hepatocellular carcinoma; 
Liver and Spleen; carcinoid; pectoral muscle (after mastectomy) ; 
kidney; duodenal adenocarcinoma, cell line; placenta_normal; 
hypernephroma, cell line ; melanotic melanoma, high MDR (cell 
line) ; cartilage ; pooled colon, kidney, stomach; Purified 
pancreatic islet; human retina; fetal eyes, lens, eye anterior 
segment, optic nerve, retino, Retina Fovea! and Macular, RPE and 
Choroid ; RPE and Choroid; Ascites ; breast; ovary, turner 
tissue; Liver; myeloma; astrocytoma grade IV, cell line; pooled 
pancreas and spleen; human skeletal muscle ; large cell 
carcinoma; heart_neonatal; embryonal carcinomo, cell line; 
pineal gland; mixed (pool of 40 RN As) ; RPE!choroid; whole 
brain 
Gene to Tag mapping 
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2.5.2 MOLECULAR ANALYSIS OF CHROMOSOME 10 
Clinical and genetic studies have highlighted the existence of at least two additional 
Miyoshi Myopathy (MM) loci, with a second MM locus being tentatively assigned to 
chromosome lOp (Linssen et al., 1998). The chromosome 10 markers DIOS547, 
DIOS2325, DIOS570 and DIOS191 which were used in Linssen's study, were used for 
haplotype analysis of our families 7-15 in order to establish linkage to chromosome I 0. 
Further haplotype analysis was performed using additional microsatellite markers 
mapping distally and proximally to the original region of interest in order to identify 
recombinant boundaries in any families showing linkage. 
The map order and location ofthe markers was established by the same methods as those 
described in section 2.5.1 for the genetic analysis of chromosome 19. Similarly, the 
primer sequences and PCR product sizes were obtained as described previously in section 
2.5.1. 
2.5.3 MOLECULAR ANALYSIS OF CHROMOSOME 3 
In the non-dysferlin MM families haplotype analysis was also performed for the caveolin 
3 region on chromosome 3. Caveolin 3 mutations cause several types of muscular 
disorders, including LGMD I C, hyperCKemia, rippling muscle disease, and distal 
myopathy. Caveolin 3 interacts with dysferlin by co-immunoprecipitation analysis. 
Caveolin 3 expression has been shown to be reduced in dysferlin deficient muscle and 
vice versa in some caveolin 3 deficient muscle dysferlin expression is reduced. Caveolin 
3 therefore appears to be a good candidate for Miyoshi Myopathy not linked to dysferlin. 
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Four microsatellite markers mappmg within and flanking the caveolin 3 gene were 
analysed: D3S3611, D3S3691, D3Sl307 and D3S2170. 
The map order and location of the markers was established by the same methods as those 
described in section 2.5.1 for the genetic analysis of chromosome 19. Similarly, the 
primer sequences and PCR product sizes were obtained as described previously in section 
2.5.1. 
2.6 SSCP ANALYSIS 
SSCP (single-stranded conformation polymorphism) is a method for detection and 
localisation of uncharacterised point mutations based on the property of single stranded 
DNA molecules of the same length to assume different conformations depending on their 
nucleotide sequence. The method is a scanning one allowing only detection and 
localisation of mutations; further scanning followed by DNA sequencing would be 
necessary in order to specify the mutation. Detection of mutations responsible for 
particular phenotypes allows for molecular characterisation, diagnosis, prevention and 
treatment of inherited diseased such as Muscular Dystrophy. 
Single-stranded DNA molecules fold into complex three-dimensional structures as a 
result of intrastrand base pairing. Changes of as little as a single base causes variation in 
the looping and compaction of the secondary structure, which changes electrophoretic 
mobility through native polyacrylamide gels. Hence single strands of equal length but 
different sequence can vary considerably in electrophoretic mobility. SSCP exploits the 
differences in mobility between wild-type and mutant strands of DNA (Orita et a/, 
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1989a,b, 1990; Ainsworth et a/, 1991; Dean and Gerrard 1991; Condie et al., 1993; 
Glavac and Dean 1993; Fan et al., 1993; Axton and Hanson 1998; Jaeckel et al., 1998; 
Nataraj et al., 1999. 
SSCP involves three steps: 
1) amplification by PCR ofthe target region ofthe gene 
2) denaturation of the PCR product 
3) electrophoresis of the single stranded DNA through MDE gel at neutral pH 
1) PCR amplification of gene exons for SSCP 
Primers were identified by bioinformatic analysis using the resources LocusLink and 
Sequence Viewer at the NCBI (National Center for Biotechnology Information) website, 
whose home page is at http://www.ncbi.nlm.nih.gov. Exons were identified for each 
gene using LocusLink. These sequences were accessed using Sequence Viewer and 
primers then designed. Table 2.3 summarises the primers used and their sequences. 
DNA was amplified from genomic DNA templates under standard conditions as 
described for microsatellite loci in section 2.3. Care was taken to minimise the 
production of non-specific amplification products, as these would complicate the 
interpretation of results. Optimisation was carried out as described in section 2.3, but in 
this case it was sometimes necessary to increase the annealing temperature to 60°C. 
The use of double stranded DNA as a template allowed both strands of the target region 
to be analysed simultaneously. This poses an advantage over the use of single stranded 
templates as each strand behaves differently and one will often produce better conformers 
for SSCP than the other. 
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Primer Forward sequence 5' ~ 3' 
FXYD1EXON1 ACT GCC T AA TCC GTG GTG TC 
FXYD1EXON2 CCC TGA TTT CTC TCT CTT TCC A 
FXYD1EXON3 TGC TCT GCT GCT CAC AGA CT 
FXYD1EXON4 CTT CTC CTA CCT CTC CAC GC 
FXYD1EXON5 CTC TGC CTC TGT CTT CCC AG 
FXYD1EXON6 CAG GTC TGT CCA CCG CAG G 
FLJ20200 EXON 1 A AGT CTG GTG AA T GGA CAC 
FLJ20200 EXON 1 8 GGT GGT GGT GGC TCC CTC TG 
FLJ20200 EXON2 GAA TGG GGA CTC ACA GGA 
FLJ20200 EXON3 TGA GGG AAA GTG GGG TAT AG 
FLJ20200 EXON4A TTC TGG CAC CAG CCA CAA G 
FLJ20200 EXON48 TAG AA T GTC ACT GAG TGC CG 
FLJ20200 EXONS AGA TTT GGC TTC GGC TCC 
FLJ 1 0922 EXON 1 CCG A TT TCT CCC TCA CCT TA 
FLJ 10922 EXON2A GGA CAG GCG GTA CCT GTA TT 
FLJ 1 0922 EXON 28 AAC AGT GGC CAT ACT CGG AC 
FLJ10922 EXON3 GAA CAA GCA CCA CAG GGC 
FLJ10922 EXON4 CTG GGG ATC CGT TAG TGA TG 
SEPW1 EXON1 CAG GTG GGA GGT TAG TGT GG 
SEPW1 EXON2&3 ACT CTC CTA CCA GTG GCG CT 
SEPW1 EXON4&5 CCG GGT TCT TTG AAG TGA TG 
Table 2.3 Primers used for SSCP analysis 
Reverse sequence 5' ~ 3' 
CAA CTT GGT TCT TCG GTC CC 
AA T CAA AGG ACC AGC AAA GC 
AGC TAG GGG CAC TCA CTC AG 
GTA CTC CCC GCC TCA CCC 
CCC AGA ATA CCC GCA GTC TC 
CTC CCT TCC TCC CTC CTT C 
CAG GAG CCC AGC GGG ATG G 
TCC CAC CCG AGT GAC CCC G 
GGT GGC CGT GGT CAT GG 
TCT GGA GGG AGC CTG AA T 
CGT CTC CCC TGC TAC CCC GGG GC 
GAC TCT GAC CCC CTA CTC CC 
CCT CTC TTT CCC TCC ACA 
CTT TGC GCA TGC GTT TT ACT 
GGT CCA GGG TCC GAG TAT G 
CTA GAT GGC CTT TGA CCC CT 
TTT GCT TCC TGA GGT AAC AGG 
CCT ATC CCA TCT TTT TCT CTC TGA 
GCT GGG CTT ACC AA T AAA CG 
AGT CTT TCT CCC CAT CCC AA 
CCC TCA CCT CTG CCT TCA G I 
2) Denaturation 
Prior to loading on the gel, double stranded DNA was denatured by incubation at 94°C 
for 4 min in the presence ofSSCP buffer (95% formamide, 20mM EDTA, 0.05% xylene, 
0.01% bromophenol blue). 5-8Jll of completed PCR product was used depending upon 
concentration (determined by electrophoresis, see section 2.2), combined with equal 
volume of SSCP buffer. 
3) Electrophoresis 
Conformers of single stranded DNA were separated by gel electrophoresis under 
nondenaturing conditions. Optimum resolution is obtained using cross-linked 
polyacrylamide from the Hydrolink series of gel matrices (Molinari et al., 1993) which 
are marketed under the trade name of MDE (Mutation Detection Enhancement), (FMC 
BioProducts). 50% MDE gels were used (50% Hydrolink!MDE, 6% 1 OX TBE, 5% 
glycerol, 6% Ammonium persulfate, 0.15% TEMED). Electrophoresis was carried out in 
0.6X TBE buffer for 24 hours at 240V using the BIO-RAD PROTEAN®Ilxi Cell. This 
apparatus maintained gels at a constant temperature, necessary to prevent dissociation of 
intrastrand base pairs, destabilisation of conformers and hence loss of resolution. 
Following electrophoresis, conformers were detected by silver staining. The MDE gel 
was fixed by immersing in fixative (10% ethanol, 0.5% acetic acid) for 3 minutes, 
followed by a further 3 minutes in fresh solution. The gel was then incubated in silver 
nitrate (0.1% w/v) for 15 minutes. The gel was then rinsed in distilled water and 
incubated in an aqueous solution of 1.5% sodium hydroxide and 0.15% formaldehye for 
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20 minutes. The stained gel was then fixed by immersion in a 0.75% aqueous solution of 
sodium carbonate for 10 minutes. 
An example of a stained SSCP gel is shown in Fig. 2.10. 
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Fig. 2.10 Single stranded conformational polymorphism (SSCP) 
Conformers of single stranded DNA separated by gel electrophoresis through an MDE 
Hydrolink gel under native conditions. Samples produced by amplification of exons 2A 
and 2B of the gene FLJ20200 in Family 2. All samples are normal with no evidence of 
mutation, since conformers are identical between individuals. 
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CHAPTER3 
RESULTS 
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3.1 HAPLOTYPE ANALYSIS OF THE LGMD21 REGION 
Six potential LGMD2I families were analysed using the following microsatellite markers 
mapping to the LGMD2I region: Dl9S606, D19S596, D19S902 and D19S879. 
Haplotype analysis had previously excluded the families from the limb-girdle muscular 
dystrophy loci LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E and LGMD2F. 
No chromosome 19 data was available for the families with the exception of Family 1. In 
this family haplotype analysis had been performed using the following markers: 
Dl9S918, D19S412, D19S606, D19S879, D19S867. The haplotype data assembled for 
Family I is shown in Fig. 3 .I. The data is suggestive of linkage, with both affected 
individuals showing shared alleles for five of the markers studied, but the data is 
uninformative. 
In Family 2 marker D 19S606 is uninformative, and the markers D 19S596, D 19S902 and 
D 19S879 identify recombinants by comparing the haplotypes of the two affecteds. Both 
affecteds show different haplotypes, suggesting exclusion from the LGMD2I locus (Fig. 
3.2). 
In Family 3 the data is consistent with linkage (Fig. 3.3). Both affected individuals share 
the same haplotypes, which are not shared by the two unaffected sibs. There is no 
evidence of recombination among the affected individuals. 
In Family 4 the two affecteds do not share the same haplotypes for markers to the 
LGMD21 region. Haplotypes are however shared by the affected individual 4-C3/F A and 
the unaffected sib 4-C1/MU. Similarly the affected individuai4-C8/FA shares the same 
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Fig. 3.1 Chromosome 19q haplotyping in Family 1 
Data in italics generated by Angela Huebner's Group in Germany. Order of markers 
was determined from sequence data for the region and is given centromere ~ telomere 
(top~ bottom). Affected indi-viduals are represented by solid symbols and unaffected 
individuals by open symbols. 
1-P/MU 
DJ9S918 
DJ9S412 
DJ9S606 
D19S596 
Dl9S902 
DJ9S879 
DJ9S867 
Dl9S918 
DJ9S412 
Dl9S606 
Dl9S596 
D19S902 
DJ9S879 
Dl9S867 
1-Cl/FA 
diseased chromosome 
1-P/FU 
1-C2/MA 
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Fig. 3.2 Chromosome 19q haplotyping in Family 2 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given centromere~ telomere (top ~bottom). 
Dl 9S606 
Dl 9S596 
Dl9S902 
Dl9S87 
2-P/MU 
Dl9S606 
Dl9S596 
Dl9S902 
Dl9S879 
2-Cl/MA 
w 
diseased chromosome 
uninformative 
2-P/FU 
2-C2/FA 2-C3/FU 
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Fig 3.3 Chromosome 19q haplotyping in Family 3 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given centromere~ telomere (top~ bottom). 
Dl9S606 
Dl9S596 
Dl9S902 
Dl9S879 
3-P/MU 
Dl9S606 
Dl9S596 
Dl9S902 
Dl9S879 
3-Cl/FU 3-C2/MU 
diseased chromosome 
3-P/FU 
3-C3/MA 3-C4/FA 
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haplotype as the unaffected 4-C5/MU. This data is consistent with exclusion from the 
LGMD21 locus (Fig. 3.4). 
In Family 5 the two affecteds share the same haplotype, which is not seen in the 
unaffected sibs. The marker D 19S606 is uninformative. For the other markers there is no 
evidence of recombination. The data suggests linkage to the LGMD2I locus (Fig. 3.5). 
In Family 6 the two affected individuals share the same haplotype. However the markers 
D 19S606 and D 19S596 are uninformative, and there is no evidence of recombination. 
The data suggests linkage to the LGMD21 locus, but is not fully informative as there are 
no unaffected sibs in the family (Fig. 3.6). 
3.2 PHYSICAL MAPPING OF THE LGMD2I REGION 
Identification of ESTs mapping to the LGMD21 critical region between the centromeric 
marker D 19S606 and the telomeric marker D 19S879 was performed by computer based 
analysis using information from the GeneMap 1998. Having now been fully sequenced, 
the GeneMap for this region is no longer available. The ESTs identified are given in 
Table 3.1. The ESTs were subjected to BLAST (Basic Local Alignment Search Tool) 
analysis (http://www.ncbi.nlm.nih.gov/BLAST/) with the HTGS (High Throughput 
Genomic Sequencing) database in order to identify genomic sequence contigs. It was 
possible to identify overlaps where several ESTs and microsatellite markers were 
assigned to the same contig. From these analyses a primary physical map of the 
LGMD2I region was constructed (see Fig. 3.22). 
79 
00 
0 
Fig. 3.4 Chromosome 19q haplotyping in Family 4 
Affected individuals are represented by solid symbols and unaffected individuals by open symbols. Order of markers is 
given centromere~ telomere (top~ bottom). 
Dl 9S606 
D19S596 
D19S902 
D19S879 
4-C l/MU 4-C2/MU 4-C3/FA 
w w w 
diseased chromosome 
4-P/MU I I 
Dl9S606 Wl Dl9S596 Dl9S902 Dl9S879 
4-C4/MU 
m 
I 4-P/FU 
w 
4-C5/MU 4-C6/MU 4-C7/FU 4-C8/FA 4-C9/MU 
ww mw m 
Fig. 3.5 Chromosome 19q haplotyping in Family 5 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given centromere ~ telomere (top ~ bottom). 
5-P/MU 
Dl9S606 
Dl9S596 
Dl9S902 
Dl9S879 
5-Cl/MU 
W Wl 
5-C2/FU 5-C3/FA 
Dl9S606 
Dl9S596 
Dl9S902 
Dl9S879 W Wl I 
Ill diseased chromosome D uninformative 
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5-P/FU 
5-C4/MA 
Fig. 3.6 Chromosome 19q haplotyping in Family 6 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given centromere ---+ telomere (top ---+ bottom). 
6-P/MU 
D19S606 
D19S596 
D19S902 
D l9S879 
D19S606 
D19S596 
D l9S902 
D l9S879 
6-Cl/FA 
diseased chromosome 
6-P/FU 
6-C2/FA 
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Table 3.1 ESTs mapping to the LGM021 critical region 
EST GENE CONTIG CLONE 
Wl-9140 GRLF1 !glucocorticoid receptor AC012313 
SGC36947 ESTs GTSCR2 
stSG44765 ESTs also expressed in muscle 
stSG53674 ESTs AC073131 
Wl-19271 Human mRNA 
H56372 ESTs 
stSG49271 ESTs 
RP L18 RPL18 Ribosomal protein L 18 
Cda13a10 ESTs 
R99562 HNF3G hepatocyte nuclear factor 3 
stSG3117 ATP5G1 ATP synthase, H+ transporting AC006262 
sts-AA0271 08 ESTs 
AFM284yg5 019S412 Microsatellite marker AC007193 
A006X30 Homo sapiens mRNA AC010326 
stSG2167 ESTs AC008635 
stSG52313 ESTs AC024740, 23094 
stSG12792 EST 
AFMa133zh9 019S596 Microsatellite marker AC024740, 09002, 23094 
NIB719 Homo sapiens actin associated protein AC016589, 10331, 73548 
stSG47680 ESTs AC008755, 24443 
stSG1238 SULT2A1 sulfotransferase family 2A AC008745, 24582, 11457, 40922 
stSG44984 ESTs 
sts-T47573 ESTs AC008754, 08576 
stSG465 NAPA N-ethylmaleimide-sensitive factor 
sts-U13061 Unknown 
sts-T77818 ESTs 
stSG35241 EST 
H48539 EST AC008895, 27709 
stSG3439 ESTs 
stSG52618 ESTs AC008532 
Wl-22443 ESTs AC008532 
H25547 ESTs AC008754 
stSG30190 Homo sapiens mRNA AC008755, 24443 
stSG8858 ESTs AC008755, 24443 
stSG58588 ESTs 
sts-N25366 ESTs AC00875 
sts-F16347 Unknown 
EST196348 ESTs AC008888 
stSG4486 NAPA N-ethylmaleimide-sensitive factor 
Wl-13762 ESTs 
Wl-20785 SEPW1 selenoprotein W, 1 
M057647 ESTs AC008755 
U82987 Human Bcl-2 binding component 3 AC008532, 17110 
Cda11g02 PLA2G4C phospholipase A2, group IVC 
sts-R61534 ESTs 
stSG26816 OBP 0 site of albumin promoter AC040922, 08888 
Wl-14200 PLA2G4C phospholipase A2, group IVC AC010458, 11466 
EST GENE CONTIG CLONE 
sts-M35531 FUT 1 fucosyjtransferase 1 
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stSG47114 ESTs AC008403, 73131 
066904 HRMT1l1 HMT1 
stSG2506 ESTs 
A004H25 PLA2G4C I phospholipase A2,_group IVC 
stSG12712 EMP3 epithelial membrane protein 3 AC073131, 08392 
stSG30258 ESTs 
Wl-9028 Human mRNA AC073131 
WIAF-946 Homo sapiens clone IMAGE 
sts-U59752 PSCD2 1 pleckstrin homology AC073131 
stSG39919 GRLF1 [glucocorticoid receptor 
stSG40815 ESTs AC008745, 24582, 11457 
stSG9290 Homo sapiens clone IMAGE AC011466, 11212 
stSG30815 EST AC008745 
Wl-14251 Homo sapiens mRNA AC011466, 11212 
Wl-11704 ESTs AC008745, 21988, 11481, 26635 
stSG36079 EST AC008403 
Wl-16013 ESTs AC040922 
A004F11 ESTs 
stSG42757 FUT1 fucosyltransferase 1 AC008392 
stSG54061 ESTs AC026803, 08749 
stSG63102 ESTs AC008392 
stSG40077 ESTs AC008403 
stSG54041 Homo sapiens orphan neurotransmitter AC008403 
stSG55012 CA11 carbonic anhydrase XI AC068888, 40922, 23094 
stSG27366 Homo sapiens RUVBL2 protein AC008687 
Wl-19404 EST AC073548,16589,10331 
stSG39537 H. sapiens apoptosis associated protein AC026803, 24749, 08749 
stSG15451 Homo sapiens clone DT1P1A2 mRNA AC026803, 087 49 
stSG44262 ESTs, retinal short chain dehydrogenase AC026803,24740, 08749 
sts-R32980 Homo sapiens apoptosis associated 
stsSG8002 ESTs AC026803,24740, 08749 
A002E14 Homo sapiens RUVBL2 protein 
sts-W47119 ESTs 
A002145 ESTs 
stSG39666 HRC histidine-rich calcium-binding protein AC008891 
sts-AA036925 EST, similar to ferritin light chain AC026803, 087 49 
sts-T85363 ESTs AC026803,24740, 08749 
sts-Z41308 Homo sapiens actin associated protein AC073548, 16589,1 0331 
Wl-21237 BCAT2 branched chain aminotransferase 2 AC026803, 24740, 8749 
Wl-15464 Human clone 23867 mRNA sequence 
stSG26844 BAX BCL2-associated X protein AC008749, 26803 
Wl-15345 CD37 CD37 antigen 
A005S30 PSCD2 j>leckstrin homology AC073131 
stSG1742 ESTs 
stSG39641 CGB chorionic gonadotropin AC008687 
sts-R49148 ESTs, weakly similar to VRK2 AC014527, 211543 
stSG62383 ESTs 
stSG96 SNRP70 small nuclear ribonucleoprotein 
EST GENE CONTIG CLONE 
sts-J00117 CGB chorionic gonadotropin 
stSG30581 EST, from retina AC008687 
stSG15187 ESTs 
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SGC30695 ESTs 
SGC34723 ESTs AC008891 
stSG30347 EST AC011501 
SGC34294 EST 
SGC33829 ESTs AC021154, 10624,11452 
Wl-15269 ESTs AC011452,21154 
Wl-12840 ESTs 
sts-H48515 ESTs, activating transcription factor AC011452, 21154 
stSG42234 ESTs AC011495 
stSG53476 ESTs AC021163 
stSG44400 HRMT1L2 HMT1 
stSG22694 ESTs AC021163, 11452, 21163 
stSG49525 ESTs AC008655, 19157,73646 
b05503rbk Homo sapiens clone DT1P1A2 mRNA 
stSG46478 ESTs 
stSG48278 ESTs 
sts-M024912 CD37 CD37 antigen 
sts-M031950 ESTs 
sts-M86528 ESTs, neurotrophin 4/5 AC008687 
Cda0se05 ESTs, hypothetical protein 
stSG25992 ESTs, neurotrohin 
stSG48023 ESTs, similar to C. elegans 
sts-U03858 FLT3LG fms-related tyrosine kinase 3 
stSG52049 ESTs AC021154, 10624, 11452 
sts-T97512 ESTs, weakly similar to zinc finger protein 
Cda19e04 Homo sapiens mRNA AC011452,21154 
stSG53174 ESTs AC008743 
stSG31958 EST AC008743 
stSG9592 ESTs AC021163 
sts-N90422 HRMT1L2 HMT1 
stSG58521 Homo sapiens CGI-25 protein mRNA AC011495 
R43247 ESTs AC021163 
sts-H72005 ESTs AC011495 
Bdya0h04 ESTs, similar to mouse myosin AC08655, 19157 
sts-T86699 ESTs AC08655, 19157 
AFMb059wg9 D19S907 Microsatellite marker 
sts-M018544 ESTs AC021163 
181639 Human orphan receptor mRNA AC073646,08655 
stSG49939 POLD1 polymerase (DNA directed) AC008655, 20909,73646 
stSG54844 ESTs AC011495 
stSG41482 EST AC011495 
stSG38929 Human mRNA for p62 AC011452/21163 
SGC33962 ESTs 
stSG42123 ESTs AC011495 
stSG46736 ESTs, polynucleotide kinase phosphatase AC021163 
stSG13086 EST AC021163 
EST GENE CONTIG CLONE 
stSG10339 ESTs 
sts-W95460 ESTs 
stSG35523 ESTs 
stSG27382 POLD1 polymerase (DNA directed) 
stSG63150 EST, found only in testes 
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stSG51006 ESTs AC073646 
stSG42415 ESTs 
stSG47313 ESTs AC020909, 73646 
NIB1805 IRF3 interferon regulatory factor 3 AC011495 
SGC34742 IRF3 EST 
stSG32045 ESTs AC073646 
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Following identification of the contigs, we began analysing any known and novel genes 
mapping to the contig using LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink/). 
Using this resource a gene profile of expression, gene structure, domains, homologies and 
function where known to be was built for each novel transcript, with the aim of 
generating a contiguous transcript map of the LGMD21 critical region. 
However, during this time the LGMD21 gene was identified by Francesco Muntoni's 
group in London. Mapping to an identical region on chromosome 19q 13.3 as the severe 
congenital muscular dystrophy MDC 1 C, Muntoni demonstrated that LGMD21 and 
MDC 1 C are allelic disorders, caused by mutation in the fukutin-related protein gene 
(FKRP) (Brockington et al., 2001 ). The gene maps to a region on chromosome 19q 
between the markers D 19S219 and D 19S606 ( centromere-D 19S219-FKRP-D 19S606-
telomere), a region spanning 3cM. This publication is given in the Appendix. 
The focus of this study then shifted to the identification of FKRP linked families from 
our potential LGMD21 families (families 1-6). 
3.3 FKRP MUTATIONS 
A collaboration was entered into with Francesco Muntoni of the Dubowitz 
Neuromuscular Centre, Department of Pediatrics, Faculty of Medicine, Imperial College, 
Hammersmith Hospital Campus, London, UK. A panel of DNA comprising affected 
individuals from families 1-6 was screened for mutation at London, along with an 
unaffected individual from each family. 
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Our haplotype analysis of families 1-6 identified four families which were consistent with 
linkage to the LGMD21 locus. Mutations in the fukutin-related protein gene (FKRP) 
were subsequently identified in three of the families, two of the three having a C826A 
mutation. Family 3 was homozygous for this change, and Family 5 was a compound 
heterozygote, the second allelic mutation being identified as C934T. In Family 6 a 
C427 A mutation was identified, the second allelic mutation remaining unidentified. 
These findings are summarised in Table 3.2. 
Table 3.2 Summary ofFKRP mutations in LGMD21 
FAMILY CHANGE PROTEIN EFFECT MUTATIONAL STATUS 
3 C826A Leu276Ile Homozygous 
5 C826A Leu276Ile Compound heterozygote 
C934T Arg312Cys 
6 C427A Arg143Ser Compound heterozygote 
Other mutation not known 
Analysis of 17 families by Francesco Muntoni's group resulted in the identification of a 
C826A mutation in 15 of the 17 families, suggesting that this is a common mutation in 
LGMD21. As the C826A mutation was identified in a large number of the families 
studied, the possibility of this being a polymorphism was ruled out by restriction enzyme 
analysis, on the basis of the loss of a Bfal restriction site induced by the change. On 
screening a panel of 200 control chromosomes only one individual heterozygous for the 
C826A mutation was identified, and in at least I 00 of the control chromosomes the 
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mutation was not present. On the basis of these observations, and the fact that the 
mutations segregated with the disease in an autosomal recessive fashion, the mutations 
were considered to be pathogenic. 
3.4 GENOTYPE-PHENOTYPE CORRELATIONS 
FKRP mutations were identified in families 3, 5 and 6 during the study at London. In 
family 3 a homozygous C826A mutation was identified. The two affected individuals in 
this family were symptomatic from age 10 years, and currently remain ambulant during 
the fourth decade of life. Affected individual 3-C3/MA showed markedly elevated serum 
creatine kinase ( 41 05), with impairment of the proximal limb muscles, predominantly the 
lower limb. Cardiac abnormality was also apparent. 
In family 5, a C826A mutation was again identified, along with a C934T mutation. This 
family displayed a more severe clinical course than that of Family 3, which was 
homozygous for the C826A mutation. The two affected individuals in Family 5, 5-
C3/FA and 5-C4/MA (see Fig. 3.5), displayed onset of symptoms at age 9 and 7 
respectively, with loss of ambulation at age 20 and 12 respectively. Both developed 
contractures on all leg articulations in late childhood, with trunk muscle involvement and 
the development of scoliosis. Progression of the disease was less severe in individual 5-
C3/F A until the fourth decade, when both showed involvement of distal muscles of arms 
and legs, facial muscles, and hypertrophy of the tongue. Predominantly proximal atrophy 
was a feature, but was also apparent distally. There was also severe involvement of the 
respiratory muscles. Serum creatine kinase was elevated in both patients during 
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childhood, with individual 5-C4/MA showing normalisation during the third decade of 
life. 
In family 6 a C427 A mutation was identified, with the second allelic mutation remaining 
unidentified, suggesting that mutations also exist outside the FKRP coding region. Age 
of onset was 9 years for individual 6-C2/F A, with serum creatine kinase elevated to 
above I 000. The patient presented with difficulty climbing stairs, with 4 to 5 grade 
weakness. Significant weakness was noted in the tibialis anterior. No muscle 
hypertrophy was evident and the patient remains ambulant during the second decade of 
life. The disease in this family shows a less severe clinical course than that of Family 5, 
whose FKRP mutation was identified as compound heterozygote for the C826A change. 
A summary of the clinical features of these LGMD2I patients is given in table 3.3. 
The range of phenotypic severity due to FKRP mutations is large, and so far not observed 
in other forms of muscular dystrophy. I5 of the families studied at London had an 
identical C826A missense mutation in the FKRP gene. Five patients homozygous for this 
mutation had a relatively mild phenotype, whereas compound heterozygotes had on the 
whole a more severe phenotype, as reflected in the clinical features of families 3 and 5. 
Although the patients studied at London had a variable phenotype, all were less severe 
than MDC I C where patients never acquired independent ambulation. It has been 
demonstrated that both clinically and genetically, LGMD and CMD can overlap. 
Approximately 40% of cases of CMD are caused by mutations in the LAMA2 gene on 
chromosome 6q22-23, encoding the laminin a2 chain of merosin (Tome et al., I994, 
Helbling-Leclerc et al., I995, Pegoraro et al., 1998). Children having mutations in the 
LAMA2 gene usually have a severe form ofCMD, MDCIA. However, a large Turkish 
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FAMILY SEX AGE AGE ONSET FIRST SERUM MUSCLE WEAKEST 
(YEARS) (YEARS) SYMPTOM CK HYPERTROPHY MUSCLE 
3 M 34 10 Toe walking, 4105 No Hip girdle 
no running 
F 22 10 No running ND No Hip girdle 
5 M 39 7 Waddle, arm 1150 Tongue Shoulder 
weakness girdle 
F 42 9 ND 1115 Tongue Shoulder 
girdle 
6 F 18 9 Stairs >1000 No Tibialis 
anterior 
M ND ND ND ND ND ND 
NO= NO DATA, LV= LEFT VENTRICULAR 
Table 3.3 Summary of the clinical features of LGMD21 patients 
CARDIOMYOPATHY WHEELCHAIR MUTATION MUTATIONAL 
BOUND STATUS 
Moderate LV, No C826A Homozygous 
hypokinisia 
ND No C826A Homozygous 
I 
No 20 C826A Compound 
C934T heterozygote 
No ND C826A Compound 
C934T heterozygote 
No No C427 A, other Compound 
mutation not known heterozygote 
ND ND C427 A, other Compound 
mutation not known heterozygote 
kindred having a clear LGMD phenotype, has been shown to be linked to the LAMA2 
locus (Tan et al., 1997). Mutations in this gene can result in either a severe disease 
(MDC lA) or a mild LGMD-Iike disease, depending on the type and location of the 
mutation within the gene. 
A number of CMD forms have also been described which are not due to mutations in the 
LAMA2 gene, including Fukuyama CMD (FCMD). The FCMD gene encodes fukutin, a 
protein of unknown function (Kobayashi et al., 1998). The fukutin-related protein gene, 
FKRP, along with fukutin, demonstrate sequence similarities to a family of proteins 
involved in modifying cell surface molecules (Aravind & Koonin, 1999). The FKRP 
gene is also mutated in a severe form of CMD, MDC I C (Brockington et al., 2001 ), and 
maps to an identical region on chromosome 19q as LGMD21 (Breton & lmberty, 1999). 
Mutations in the FKRP gene account for a significant proportion of the patients in the 
London study whose severity ranged from a severe congenital form (MDC 1 C) to a much 
milder form (LGMD21), most patients with a relatively mild disease course having the 
C826A mutation. 
93 
3.5 GENETIC ANAL Y§I§ OF MJ:YO§HI MYOJP A THY NOT LINKED TO 
DY§FERLIN 
3.5.1 CHROMOSOME 10 HAPLOTYPE ANALYSIS 
In this study the genetics of Miyoshi Miyopathy (MM) not linked to dysferlin was also 
studied. 9 of our families showed exclusion from dysferlin on the basis of haplotyping or 
from the normal dysferlin expression observed in patient biopsies. 
In two families (7 and 8) genetic analysis data suggested tentative linkage to the 
chromosome 10 locus (LOO score Zmax (D 1 OS2325) 2-63 e = 0). To confirm linkage to 
chromosome 10 and to define the MMD2 region, further haplotype analysis was 
performed using the following additional microsatellite markers mapping distally to 
D10S189 (-D10S1713, D10S591, D10S1745-telomere), and proximal to D10S1423 (-
D10S553, D10S1734, D10S1749, D10S1733, D10S1674, D10S1768-centromere). In 
family 7, recombinants were observed in both the affected individuals at the marker 
D 1 OS 1713, defining the distal recombinant boundary. The proximal recombinant 
boundary was not defined in this family since the markers D 1 OS 191, D 1 OS 1423, 
DIOS553, D10Sl734, D10Sl749, D10S1733, D10Sl674 and D10S1768 are 
uninformative (Fig. 3.7). In family 8, the distal recombinant boundary is defined by the 
marker D10Sl713 in individual 8-C2/FU, confirming the observations made in family 7. 
The proximal recombination boundary is represented by the marker D 1 OS 167 4 in 
affected individual 8-C6/F A (Fig. 3.8). In physical terms this represents a 25Mb region 
of non-recombination. 
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In families 9-15 the markers D10S547, D10S2325, D10S570 and D10S191 were 
analysed in order to identify further chromomsome 10 linked families. 
In Family 9, the affected individual shares the same haplotype as the unaffected sib, 
suggesting that this family is excluded from the MMD2 locus (Fig. 3.9). 
In Family 10 the data appears to suggest linkage to chromosome 10. The affected 
individual does not share haplotype with either of the unaffected sibs in the family. With 
further haplotype analysis the data remains consistent with linkage, but all markers were 
non-recombinant across a large physical region (25Mb). The proximally located markers 
DIOS553 and D10S1674 are uninformative (Fig. 3.10). Ifthe data from this family is 
evaluated with the data produced for families 7 and 8 using the GENEHUNTER program 
and two point linkage analysis performed, a possible LOD score of 2.83 (8 = 0) at the 
marker D 1 OS2325 can be generated. 
In Family 11, recombination is seen in both affected individuals at the marker D 1 OS 191, 
but the two affecteds do not share the same haplotype. Exclusion cannot be confirmed, 
and requires analysis of additional markers as in family 10 (Fig. 3.11 ). 
In Family 12, the affected individual does not share haplotype with either of the two 
unaffected sibs,and there is no evidence of recombination (Fig. 3.12). Again, to obtain 
informative results further markers need to be analysed in order to establish linkage. 
In Family 13 the data identifies recombination at the marker D 1 OS 191 in individual 13-
C3/FU. The two affected individuals share the same haplotype generated from markers 
DIOS547, D10S2325, D10S570 and Dl0Sl91, but the unaffected individual 13-C4/FU 
also shares this haplotype (Fig 3.13). This suggests no linkage to chromosome 10, but to 
confirm it is necessary to analyse more markers as in family 10. 
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Fig. 3.9 Chromosome lOp haplotyping in Family 9 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom). 
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Fig. 3.10 Chromosome lOp haplotyping in Family 10 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom). 
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Fig. 3.11 Chromosome lOp haplotyping in Family 11 
Affected individuals are represented by solid symbols and unaffected individuals by open symbols. Order of markers is 
given telomere~ centromere (top~ bottom). 
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Fig. 3.12 Chromosome lOp haplotyping in Family 12 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere~ centromere (top~ bottom). 
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Fig 3.13 Chromosome lOp haplotyping in Family 13 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom) . 
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Similarly, for Family 14 the affected individual shares the same haplotype as the 
unaffected sib 14-Cl/FU (Fig. 3.14), and further markers would need to be analysed in 
order to confirm exclusion from chromosome 10. 
In Family 15, there are no shared haplotypes between the two affected individuals. The 
affected 15-C4/MA shares the same haplotype as the unaffected 15-C3/FU, and the 
affected 15-C6/MA shares the same haplotype as the unaffecteds 15-C 1/FU and 15-
C5/FU. This data is consistent with exclusion from the chromosome lOp locus (Fig. 
3.15), but requires confirmation using additional microsatellite markers. 
3.5.2 CA VEOLIN 3 HAPLOTYPE ANALYSIS 
In the non-dysferlin MM families haplotype analysis was also performed for the caveolin 
3 region on chromosome 3. Four microsatellite markers mapping within and flanking the 
caveolin 3 gene were analysed: D3S3611, D3S3691, D3S 1307 and D3S2170. 
In Family 9, the markers D3S3611 and D3S3691 identify recombination in the affected 
individual. This haplotype is not shared by the unaffected sib, but the data is 
uninformative. Further analysis using additional microsatellite markers is necessary in 
order to establish linkage or exclusion (Fig. 3.16). 
In Family 10, recombination of the paternal chromosome is seen in the affected at the 
marker D3S3611. Individual I O-C3/MU is also recombinant on the maternal 
chromosome at marker D3S 1307. Although the affected does not share haplotype with 
either of the unaffecteds, the data is uninformative and analysis of further microsatellite 
markers is necessary to confirm linkage or exclusion (Fig. 3.17). 
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Fig. 3.14 Chromosome lOp haplotyping in Family 14 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere~ centromere (top~ bottom). 
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Fig. 3.15 Chromosome lOp haplotyping in Family 15 
Affected individuals are represented by solid symbols and unaffected individuals by open symbols. Order of markers 
is given telomere~ centromere (top~ bottom). 
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Fig. 3.16 Chromosome 3 haplotyping in Family 9 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~bottom). 
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Fig. 3.17 Chromosome 3 haplotyping in Family 10 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom). 
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In Family 11, the two affecteds do not share the same haplotype. The affected individual 
11-C3/FA shares haplotype with the unaffected 11-C5/MU. This data is consistent with 
exclusion (Fig. 3 .18). 
In Family 12, recombination is seen in the affected individual at marker D3S1270 on the 
maternal chromosome. This affected does not share haplotype with either of the 
unaffected sibs (Fig. 3.19). However the data is uninformative, and further analysis with 
additional microsatellite markers is necessary as in Family 10. 
In Family 13, the two affecteds do not share haplotype. The affected individual 13-
C2/MA shares haplotype with the unaffected 13-C4/FU. This data is consistent with 
exclusion from this locus (Fig.3.20). 
In Family 15, the markers D3S1307 and D3S1270 identify recombinants by comparing 
the haplotypes of the two affecteds. The affected individual 15-C4/MA shares haplotype 
with the unaffecteds 15-C1/FU and 15-C3/FU, excluding this family from the locus on 
chromosome 3 (Fig. 3.21). 
The gene was screened by SSCP and sequencing among the affecteds from each family. 
No mutations were identified. 
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Fig. 3.18 Chromosome 3 haplotyping in Family 11 
Affected individuals are represented by solid symbols and unaffected individuals by open symbols. Order of markers is 
given telomere ~ centromere (top~ bottom). 
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Fig. 3.19 Chromosome 3 haplotyping in Family 12 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom). 
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Fig 3.20 Chromosome 3 haplotyping in Family 13 
Affected individuals are represented by solid symbols and unaffected individuals 
by open symbols. Order of markers is given telomere ~ centromere (top ~ bottom). 
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Fig. 3.21 Chromosome 3 haplotyping in Family 15 
Affected individuals are represented by solid symbols and unaffected individuals by open symbols. Order of markers 
is given telomere~ centromere (top~ bottom). 
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DISCUSSION 
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This study had two aims, firstly to work towards the identification of potential LGMD21 
families and, by screening databases, to construct a physical map of the LGMD21 critical 
region and identify candidate genes mapping within this region. Secondly, we aimed to 
define the MMD2 region on chromosome 10 and to determine whether caveolin 3 is 
mutated in Myoshi Myopathy not linked to dysferlin, as well as to identify further genes 
involved in Myoshi Myopathy not linked to dysferlin. 
We studied 6 potential LGMD21 families, 4 were suggestive of linkage. A primary 
physical map of the LGMD21 region was constructed, having at least 26 genes placed 
within the critical region between the centromeric marker D 19S606 and the telomeric 
marker D I9S879. Using LocusLink, candidate genes were identified on the basis of their 
potential role in muscular dystrophy. Four candidate genes, FXYD I, FLJ20200, 
FLJ10922 and SEPWI were screened by SSCP analysis but no mutations were detected. 
However, during this time the LGMD21 gene was identified as the fukutin related protein 
gene (FKRP) (Brockington et al., 200Ia), by Francesco Muntoni's group in London. 
The fukutin-related protein gene, FKRP, shares homology with fukutin, the protein 
product of the FCMD gene responsible for Fukuyama CMD (Kobayashi et al., 1998). 
These proteins demonstrate sequence similarities to a family of proteins involved in 
modifying cell surface molecules (Aravind & Koonin, I999), suggesting a role as a 
glycosyltransferase. All members of this family of proteins contain a conserved DxD 
motif found in many glycosyltransferases (Breton and Imberty, I999). However it 
remains to be formally demonstrated that FKRP is itself a glycosyltransferase. The 
FKRP gene is also mutated in a severe form of CMD, MDC I C (Brockington et al., 
2001 b). This disease is characterised by early onset, inability to achieve independent 
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ambulation, muscle hypertrophy, marked elevation of serum creatine kinase (CK), no 
brain involvement and a secondary deficiency of laminin a2 (Brockington et al., 2001 b). 
Affected individuals also show a marked decrease in a-dystroglycan expression as 
demonstrated by immunostaining and western blot analysis. The mutations in FKRP 
resulting in selective deficiency of a-dystroglycan in skeletal muscle most likely occur 
due to abnormal glycosylation, a-dystroglycan a heavily glycosylated peripheral 
membrane protein forming a link between the actin associated cytoskeleton and the 
extracellular matrix via laminin a2 (lbraghimov-Beskrovnaya et al., 1992, Ervasti et al., 
1993). 
Congenital muscular dystrophy (CMD) is also caused by mutations in the LAMA2 gene, 
encoding the laminin a2 chain of merosin (Brockington et al., 2001b). Around 40% of 
cases of congenital muscular dystrophy are due to LAMA2 mutations. Merosin is an 
extracellular matrix protein consisting of three lam in in chains which form a link with a2 
between the peripheral membrane protein a-dystroglycan and the basal lamina (Emery, 
AEH., ed. Neuromuscular disorders: Clinical and Molecular Genetics (Wiley, 1998) pp. 
21-48). Children with mutations in LAMA2 usually have absent protein expression and a 
severe form of CMD, MDC lA. The clinical and genetic overlap of CMD and LGMD 
suggest that the underlying pathology of the diseases follow a similar pathway. 
Following the cloning of the FKRP gene by Francesco Muntoni's group, the emphasis of 
this study then shifted from candidate gene analysis to the identification of FKRP 
mutations in linked families. Haplotype analysis revealed 3 of our 6 potential LGMD21 
families to be suggestive of linkage; FKRP mutations were subsequently identified in all 
3 families during Francesco Muntoni's study in London, as described in section 3.3. 
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During the investigation at London a total of 25 potential LGMD21 families were 
analysed; 14 of the families were consistent with linkage to the LGMD21 locus. 
Mutations were identified in individuals from 17 families by sequence analysis of the 
FKRP coding region. Unexpectedly, an identical C826A (Leu276IIeu) mutation was 
identified in affected individuals from 15 of the 17 families, and C826A has now been 
identified as the most common mutation found in any autosomal recessive muscular 
dystrophy in the North East of England (Brockington et al., 2001 a). Of the 15 individuals 
in whom the C826A mutation was identified, 5 were homozygous for the change, the 
remainder being compound heterozygotes. Of the 10 heterozygous individuals, the 
second allelic mutation was identified in four cases, these being two missense mutations 
(C934T, C947G), one nonsense mutation (390insTACC) and an in-frame deletion 
( 426del12). Of the families without the C826A mutation, a heterozygous missense 
mutation (C427 A) was identified in one case, and a homozygous missense mutation 
(G1016A) was identified in the case of one consanguineous family. In eight cases no 
mutations were found in the FKRP coding sequence, four of which were individuals from 
genetically informative families compatible with linkage to the FKRP locus. In 6 of the 
10 compound heterozygotes for the C826A mutation, the second allelic mutation was not 
identified (Brockington et al., 2001a). These findings strongly suggest that mutations 
also exist outside the FKRP coding region. 
Collectively, the patients from the 25 LGMD families studied at London had a variable 
phenotype, though all were less severe than MDC 1 C where patients never acquired 
independent ambulation (Brockington et al., 2001a). Five of the families had a severe 
LGMD phenotype, with onset of symptoms within the first two years of life. Despite the 
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overlap with MDC 1 C, the disease course was significantly milder than that of CMD and 
followed a Duchenne-like course in several aspects. The clinical features in these five 
families were characterised by delay in early motor milestones, waddling gait, difficulties 
in running, mild facial weakness, calf and occasionally tongue hypertrophy and Achilles 
tendon contractures. Serum CK was markedly elevated, with intelligence and brain MRI 
invariably normal. Three cases lost the ability to walk before the age of 14, four cases 
showed evidence of cardiac involvement (Brockington et al., 2001 a). 
The remaining 12 families studied displayed a milder phenotype; all were non-
consanguineous. Onset of symptoms was in the first decade of life for one patient, and in 
the second or third decade for the remaining patients, with early motor milestones being 
normal in all cases. Mild facial and neck flexion weakness was present in most patients, 
with calf hypertrophy and, less commonly, brachioradialis hypertrophy. Proximal 
muscles in both upper and lower limbs were weaker than distal muscles. There were no 
significant contractures, with the exception of mild reduction in lateral flexion and 
rotation of the neck in some patients. Progression of the disease followed a relatively 
benign course with all patients remaining ambulant, with the exception of one involved in 
an accident. Cardiac involvement was apparent in three of the families, and serum CK 
was also markedly elevated in these patients (between 10 and 30 times normal values). 
Intelligence and brain MRI were also normal among these patients (Brockington et al., 
2001a). 
Patients at the severe end of the LGMD21 spectrum showed a mild deficiency of laminin 
a2, with patients having a milder phenotype showing normal expression of laminin a2. 
However in four patients a severe deficiency or total absence of the protein was 
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identified. This discrepancy suggests that mutations in FKRP result in the altered 
processing, epitope masking or abnormal folding of the laminin a2 polypeptide chain 
(Brockington et al., 2001a). 
The expression of a-dystroglycan was abnormal in all muscle biopsies of LGMD2I 
patients available for study, an identical finding to MDC 1 C (Brockington et al., 2001 a). 
Genotype-phenotype correlations are now emerging, with most patients having a 
homozygous C826A mutation following a relatively mild LGMD disease course 
(Brockington et al., 2001a). Patients heterozygous for the change on the whole follow a 
more severe clinical course, though less severe than MDC 1 C. Missense mutations in the 
FKRP gene are associated with the MDC 1 C phenotype, but no null mutations are 
observed in these patients, suggesting that these mutations are embryonic lethal. 
MDC1C, along with the congenital muscular dystrophies MDC1A and MDC1B, share 
clinical features with three other myopathies, Fukuyama congenital muscular dystrophy 
(FCMD), muscle-eye-brain disease (MEB) and Walker-Warburg syndrome (WWS) 
(Emery, AEH., ed. Neuromuscular disorders: Clinical and Molecular Genetics (Wiley, 
1998) pp. 21-48). The genes for these diseases have also now been predicted to be 
glycosyltransferases, as all show deficiency of a-dystroglycan (Hayashi et al., 2001, 
Kano et al., 2002, Michele et al., 2002). Recently, the gene involved in Walker Warburg 
syndrome, POMT1, has been shown to be an 0-mannosyltransferase (Beltran-Valero De 
Bernabe et al., 2002), and the gene POMGnTI involved in MEB has been shown to be an 
0-mannoside N-acetylglucosaminyltransferase (Yoshida et al., 2001 ). The congenital 
muscular dystrophies are divided into two groups, merosin-deficient CMD and merosin-
positive CMD. Mutation in the merosin gene causes complete loss of the protein, 
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resulting in a severe muscular dystrophy phenotype (Voit, 1998). In contrast, with non-
merosin linked CMD the presence of the protein merosin results in a milder clinical 
course (Voit, 1998). 
The defining of mutations and the establishment of such genotype-phenotype correlations 
translates into a greater understanding of prognostic and treatment implications, as well 
as opening potential for accurate genetic counselling. Thus abnormal protein 
glycosylation is emerging to be a common pathomechanism in muscular dystrophy. 
Protein glycosylation occurs in the endoplasmic reticulum and the Golgi apparatus. 
Proteins having roles in cell-cell adhesion are shown to be heavily glycosylated (Kobata 
et al., 1992). Proteins can be grouped into N-glycans and 0-glycans depending upon the 
amino acid residue which is glycosylated (Martin-Rendon and Blake, 2003). 0-
glycosylation involves serine and threonine residues, N-glycosylation involving 
asparagine residues. The different sugars added impact upon the structure and function of 
the protein (Breton and Imberty, 1999). 0-mannose linked glycosylation is high in the 
brain, peripheral nerve and muscle tissue, with 30% of 0-linked sugar chains in the brain 
being 0-mannose (Van den Steen, et al., 1998). a-Dystroglycan is an 0-mannose linked 
protein, which goes some way towards explaining the occurrence of complex brain and 
eye abnormalities in CMD patients. 
Mutations in dysferlin are responsible for the muscular dystrophies LGMD2B and 
Miyoshi Myopathy (MM) (Bashir et al., 1998, Liu et al., 1998). The dysferlin gene 
encodes a novel protein which shares homology with the Caenorhabditis-elegans sperm 
vesicle fusion protein FER-I (Achanzar, W. E. and Ward, S., 1997). Although the 
function of the dysferlin protein is unknown, it has been shown to be a membrane protein 
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(Moss et al., 1999; Matsuda et al., 1999) which is characterised by the presence of 
tandem C2 domains and is predicted to have a role in membrane trafficking (Liu et al., 
1998; Bashir et al., 1998). The identification of this gene has provided a molecular test, 
allowing the identification of cases of Miyoshi Myopathy which are not linked to 
dysferlin. In this study we have worked towards identifying genes involved in MM not 
linked to dysferlin, which will ultimately serve to increase our understanding of the 
function of dysferlin. 
Pathological studies have recently shown that dysferlin deficient muscle has lesions of 
the cell membrane, with evidence of repair (Selcen et al., 2001) and abnormal 
accumulation of subsarcolemmal vesicles (Piccolo et al., 2000, Fanin et al., 2001). In 
dysferlin deficient MM, muscle membrane repair has been shown to be defective (Bansal 
et al., 2003). In normal muscle, dysferlin is enriched at the site of a wound (Bansal et al., 
2003), suggesting that it plays a role in cell membrane repair. Repair of muscle cell 
membrane involves the fusion of lysosomes with the plasma membrane upon elevation of 
intracellular calcium (Reddy et al., 2001, McNeil, 2002). Vesicles fuse with the 
membrane and with each other to form a patch over the wound site, and dysferlin is 
thought to be involved in the formation of this patch membrane and its addition to the 
wound site (McNeil, 2002). 
Our approach to identify genes responsible for non-dysferlin MM was concentrated on 
evidence of linkage to chromosome 10 (Linssen et al., 1998), and on the region on 
chromosome 3 to which caveolin 3 maps. Since caveolin 3 has been shown to co-
immunoprecipitate with dysferlin (Matsuda et at, 2001), and mutations in caveolin 3 
cause several muscular dystrophies including hyperCKemia (Merlini et al., 2002), 
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rippling muscle disease Kubisch et al., 2003), distal myopathy (Tateyama et al., 2002) 
and LGMD 1 C (Minetti et al., 1998), we considered caveolin 3 to be a candidate for non-
dysferlin MM. 
Two of our families showed tentative linkage to chromosome 10, and although the LOO 
score obtained for these families was not significant, it was close to +3. Further genetic 
analysis performed on these families identified a region of 25Mb which is shared by four 
affecteds in two families, with break points being defined. Such a large non-recombinant 
region provides further evidence for the existence of an MMD2 gene on chromosome 10. 
Our studies have identified the boundaries of this gene, and should now allow the 
identification of candidate genes for mutation screening. In smaller families haplotype 
analysis was performed in order to identify further families consistent with linkage to the 
chromosome 10 locus, but the results were not informative. Further work would need to 
be carried out using additional microsatellite markers in order to confirm linkage or 
exclusion in these families. 
Four microsatellite markers mapping within and flanking the region on chromosome 3 to 
which caveolin 3 maps were analysed in MM families not suggestive of linkage to 
chromosome 10. For some families the data was suggestive of linkage, but on the whole 
the data was uninformative. Mutation screening of the CA V3 gene was performed for 
these families by a student, and followed up by DNA sequencing, but no mutations were 
identified. This data suggests that caveolin 3 is not implicated in these cases of Miyoshi 
Myopathy. 
Data is emerging on the role of dysferlin in membrane repair, and recently other proteins 
interacting with dysferlin have been identified, including annexin A I and annex in A2 
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(Lennon et al., 2003), which are calcium binding proteins. This new information 
provides further candidates for haplotype analysis and mutation screening. In our MM 
families not linked to chromosome 10, work is continuing to assess the candidacy of 
these proteins. 
X genes have now been shown to be involved in muscular dystrophy, with overlaps such 
as that seen in LGMD and CMD emerging (Vainzof and Zatz, 2003). Mechanisms 
involved in muscle membrane stability and repair, sarcomere assembly and muscle cell 
signaling are being identified, which have helped to highlight the different mechanisms 
by which muscular dystrophy can arise (Vainzof and Zatz, 2003). 
My work in this project has helped to emphasize the role of glycosylation in muscular 
dystrophy through our work on the LGMD21 region on chromosome 19, and continuing 
work on our Miyoshi Myopathy families not linked to dysferlin will lead to the 
identification of other genes which are functioning in the dysferlin membrane repair 
pathway. 
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Pedigrees of 15 families available for haplotyping 
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FAMILY 1 
1-P/MU 1-P/FU 
1-Cl/FA 1-C2/MA 
FAMILY2 
2-P/MU 2-P/FU 
2-C1/MA 2-C2/FA 2-C3/FU 
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FAMILY 3 
3-P/MU 3-P/FU 
3-Cl/FU 3-C2/MU 3-C3/MA 3-C4/FA 
FAMILY 4 
4-P/MU 4-P/FU 
4-Cl/MU 4-C2/MU 4-C3/FA 4-C4/MU 4-CS/MU 4-C6/MU 4-C7/FU 4-CS/FA 4-C9/MU 
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FAMILYS 
5-P/MU 5-P/FU 
5-Cl/MU 5-C2/FU 5-C3/FA 5-C4/MA 
FAMILY6 
6-P/MU 6-P/FU 
6-Cl/FA 6-C2/FA 
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FAMILY7 
7-P/MU 7-P/FU 
7-Cl/MU 7-C2/FU 7-C3/FU 7-C4/FU 7-C5/FU 7-C6/MU 7-C7/MA 7-C8/FA 
FAMILY8 
8-P/MU 8-P/FU 
8-Cl/FU 8-C2/FU 8-C3/FU 8-C4/FU 8-C5/MU 8-C6/FA 8-C7/MA 
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FAMILY9 
9-P/MU 9-P/FU 
9-Cl/FU 9-C2/FA 
FAMILY 10 
10-P/MU 10-P/FU 
10-C1/MU 10-C2/MA 10-C3/MU 
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FAMILY 11 
11-P/MU 11-P/FU 
11-C1/FU 11-C2/FU 11-C3/F A 11-C4/MU 11-CS/MU 11-C6/MU 11-C7 !MA 
FAMILY 12 
12-P/MU 12-P/FU 
12-C1/MU 12-C2/MU 12-C3/MA 
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FAMILY 13 
13-P/MU 13-P/FU 
13-Cl/FU 13-C2/MA 13-C3/FU 13-C4/FU 13-CS/FA 
FAMILY 14 
14-P/MU 14-P/FU 
14-C1/FU 14-C2/FU 14-C3/FA 
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FAMILY 15 
15-P/MU 15-P/FU 15-R1/MU 15-R2/FU 15-R3/FU 15-R4/MU 
15-C1/FU 15-C2/MU 15-C3/FU 15-C4/MA 15-C5/FU 15-C6/MA 
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Mutations in the fukutin-related protein gene (FKRP) identify 
limb girdle muscular dystrophy 21 as a milder allelic variant 
of congenital muscular dystrophy MDC1C. 
Brockington et al., 2001a 
Hum Mol Genet 2001; 10(25): 2851-2859 
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he limb girdle and congenital muscular dystrophies (LGMD and CMD) are characterized by skeletal muscle 
eakness and dystrophic muscle changes. The onset of symptoms in CMD is within the first few months of 
ife, whereas in LGMD they can occur in late childhood, adolescence or adult life. We have recently demonstrated 
hat the fukutin-related protein gene (FKRP) is mutated in a severe form of CMD (MDC1C), characterized,by 
he inability to walk, leg muscle hypertrophy and a secondary deficiency of laminin a2 and u-dystroglycan. 
oth MDC1 C and LGMD21 map to an identical region on chromosome 19q13.3. To investigate whether these 
re allelic disorders, we undertook mutation analysis of FKRP in 25 potential LGMD21 families, including some 
ith a severe and early onset phenotype. Mutations were identified in individuals from 17 families. A variable 
eduction of u-dystroglycan expression was observed in the skeletal muscle biopsy of all individuals studied. 
addition, several cases showed a deficiency of lam in in a:2 either by immunocytochemistry or western blot-
ing. Unexpectedly, affected individuals from 15 families had an identical C826A (Leu27611eu) mutation, 
eluding five that were homozygous for this change. Linkage analysis identified at least two possible haplo-
pes in linkage disequilibrium with this mutation. Patients with the C826A change had the clinically less 
evere LGMD21 phenotype, suggesting that this is a less disruptive FKRP mutation thari those found in 
DC1 C. The spectrum of LGMD21 phenotypes ranged ·from infants with an early presentation and a 
uchenne-like disease course including cardiomyopathy, to milder phenotypes compatible with a favourable 
ng-term outcome. 
TRODUCTION 
e progressive muscle degeneration that gives rise to 
strophic changes on skeletal muscle biopsy is found in a 
·ery of clinically and genetically defined conditions. Two 
common forms of muscular dystrophy, distinguishable by their 
age of onset, are the congenital muscular dystrophies (CMDs) 
and the limb-girdle muscular dystrophies (LGMDs). In CMD, 
onset of symptoms is at birth or within the first 6 months of life 
(1), whereas in LGMD, they can. occur in late childhood, 
To whom correspondence should be addressed at: The Dubowtz Neuromuscular Unit, Division of Paediatrics. Obstetrics and Gynaecology, 
aculty of Medicine. Jmperial College. Hammersmith Hospital Campus. Du Cane Road. London W!2 ONN, UK. Tel: +44 20 8383 3295; 
-ox: +44 20 8740 828l;·Email: f.rnuntoni@ic.nc.uk 
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able 1. Summary of the clinical feature~ of LGMD2I patients 
amily Sex Age Age First symptom Serum CK Muscle Weakest muscle Cardiomyopathy Wheelchair Laminin a2 a.-Dystroglycan 
(years) onset hypertrophy bound 
(years) 
M 6 <0.5 Hypotonia. >1000 Calf. legs Hip girdle No No Normal ri) ND 
DMM 
F 10 Hypotonia. 3160 Tongue Neck, shoulder Borderline LVF No Reduced (I) Severe] y reduced 
DMM 
M 18 1.5 Waddle 2850 Leg, calves, Hip = shoulder SevereLY, 14 ND ND 
tongue girdle hypokinesia 
M 11 1.5 Waddle 2328 Leg, calves, Hip = shoulder ND No ND ND 
tongue girdle 
M 19 1.5 Waddle 1700-3300 Leg, tongue Hip = shoulder .Moderate LV, 12 NO Severely reduced 
girdle hypokinesia 
F 20 2 Waddle 3160 Leg, calves Deltoid LVD 13 Reduced (I) Severely reduced 
F 10 2.5 Toe walking, 1380-7795 Leg, calves Deltoid ND No Reduced (I) Reduced 
fatigue 
F 10 2.5 DMM 1278 No Hip girdle No No Reduced(D ND 
M 28 4 Toe walking, 4105 No ·Hip girdle Moderate LV, No ND ND 
no running hypokinisia 
M 22 4 No running ND No Hip girdle ND No ND ND 
F 37 7 Waddle, imn 1150 Tongue Shoulder girdle No 12 ND ND 
··weakness 
M NA NA NA NA NA NA NA NA ND ND 
F 17 9 Gowers 2910-8200 Calf, legs Neck, deltoid Borderline LVF No Reduced (I) Severely reduced 
F 18 9 Stairs >1000 No Tibialis anterior No No ND ND 
M NA NA NA NA NA NA NA NA ND ND 
M 16 13 Gowers 1305-6820 Leg, calves Deltoid ND No' Reduced (I) Severely reduced 
F 37 27 Stairs 2870 Calf Hip girdle No Pan-time, Reduced (WB) Reduced 
35 
F 39 28 Stairs 2300 Calf,. Triceps, hip girdle ND No Reduced (WB) ND 
brachioradialis 
F 46 40 Stairs, running 2230 Calf, Hip girdle No No Reduced (WB) ·Reduced 
brachioradialis 
M 48 35 Stairs 1123 Brachioradlalis Hip girdle No No Reduced, (WB) ND 
M 37 29 Stairs >1000 Calf, Hip gii-dle No Part-time, Reduced (WB) Reduced 
brachioradialis 36 
F 27 23 Stairs 4210 Leg~ calves Hip = shoulder No No Reduced (I) Reduced 
girdle 
westenn blot; ND, no data; NA, not available; L.VF, left ventricular function; LV ,left ventricular. 
escence or even adult life (2,3). Both CMD and LGMD are 
y heterogeneous diseases. Inheritance in LGMD can be 
er autosomal dominant (LGMD type I) or autosomal 
ssive (LGMD type 2), whereas CMD is always recessively 
rited. To date, at least 14 types of LGMD have been 
rted and though the majority of causative genes have been 
d to encode proteins associated with the sarcolemma, 
s encoding cytoskeletal proteins and. muscle-specific 
mes have also been implicated (2). Fewer disease genes 
been identified in CMD (reviewed in 4). Mutations in the 
A2 gene on chromosome 6q22-23, encoding the laminin 
hain of merosin (laminin-2), were identified in 1994 and 
unt for -40% of ClVfD cases (5-'7). Merosin is an extra-
cellular matrix protein that consists of three laminin chains, 
a2~lyl, with a2 forming a link between the peripheral 
membrane protein a.-dystroglycan and the ·basal lamina. 
Children with mutations· in the LAMA2 gene usually have 
absent protein expression and a severe form of CMD, 
commonly referred to as merosin-deficient CMD or MDCIA 
It is now clear, both clinically and genetically, that CMD and 
LGMD can overlap; suggesting that the underlying pathology 
in these diseases may follow a- similar pathway. We have 
previously described a large Turkish kindred, with a clear 
LGMD phenotype. linked to the LAMA2 locus (8). Patients had 
a reduction in the expression of laminin a.2 in their skeletal 
muscle biopsy. More recently, mutations in the LAMA2 gene in 
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808bp--l> 
444bp--!> 
364bp--!> 
18Bbp~ 
100bp 
marker. Norm. Het. Horn. 
· Figure 1. (A) Sequencing chromatograms showing the C826A mutation. (B) Restriction enzyme analysis of the C826A mutation. A 996 bp PCR fragment was 
digested with Bfal. Wild-rype DNA is cut into three fragments of 445, 364 and 189 bp, whereas products containing the mutation, which introduces the loss of a 
Bfal site, are cleaved into two fragments of 808 and 189 bp. Norm., wild-type DNA; Het., heterozygote; Horn., homozygote .. 
Table 2. Summary.Df FKRP mutations in LGMDI 
Family Change Protein effect MutaJ.ional status 
6, 8, 13, 14, 15 C826A Leu276Ile Homozygous 
I GI016T Arg339Leu Homozygous 
3,4,5, 12,16,17 C826A Leu276lle Compound 
? Heterozygote 
2 C826A Leu276Ile Compound 
390insTACC Glyl32Stop Heterocygote 
9 C826A Leu276lle Compound 
C934T Arg312Cys Heterozygote 
7 C826A Leu276Ile Compound 
C947G Pro316Arg Heterozygote 
10 C826A Leu276Ile Compound 
426dell2nt 143delRMVE Heterozygote 
11 C427A Argl43Ser Compound 
? Heterozygme 
?, second allelic mutation unidentified. 
_ several patients with a LGMD phenotype and a partiallaminin 
· o:2 deficiency have been identified (9-11), confmning that 
mutations in this gene can result in either a severe disease 
(MDC1A) or a mild LGMD-like disorder, depending on Jhe 
type and location of the mutation within the gene. · 
A number of CMD forms have been described that have· a 
reduction in laminin o:2 expression not due to mutations in the 
LAMA2 gene (secondary laminin o:2 deficiency). One of these 
is Fukuyama CMD (FCMD; MIM 253800), a multi-system 
disease in which brain, skeletal and cardiac muscle are affected 
(12). The FCMD gene encodes fukutin, a protein of unknown 
function (13). A profound depletion of skeletal and c;rrdiac 
i:nuscle a-dystroglycan haS recently been reported in FCMD 
(14). We have recently identified a new member of the fukutin 
protein family, FKRP (15) (fukutin-related protein). Analysis. 
of both FKRP and fukutin demonstrates sequence similarities 
to a family of proteins involved in modifying cell surface 
molecules, such as glycoproteins and glycolipids (16). All 
members of this family of proteins contain a conserved DxD 
motif found inn'lany glycosyltransferases (17), though formal 
proof that FKRP is itself a glycosyltransfemse remains to be 
demonstrated. Both proteins also ·have a putative type II 
membrane spanning a region consistent with localization to the 
Golgi apparatus, though it has been suggested that fukutin is 
also secreted (13). The FKRP gene is mutated in a severe form 
of CMD (MDCl C), characterized by early onset, inability to 
achieve independent ambulation, muscle hypertrophy, marked 
elevation of serum creatine kinases (CK), no brain involvement 
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Figure 2 (above and opposite). The pedigrees of 10 LGMD2I families showing the inheritance of the C826A mutation. The haplotypes containing the mutation 
are boxed. Markers DJ9S219 and Dl9S606 are based 3 cM apan on the Genethon map. Dl9S606 is <500 kb away from FKRP according to the latest sequence 
maps. 
and a secondary deficiency of laminin a.2 (15). In addition, 
affected individuals had a marked decrease in immunostaining 
of muscle a-dystroglycan and a reduction in its molecular 
weight on western blot analysis. We have suggested the 
abnormal expression of a-dystroglycan is most likely a result 
of its altered glycosylation. 
The FKRP gene maps to on an identical region on chromo-
some 19ql3.3 as LGMD2I (17), between markers DJ9S219 
and D19S606, suggesting that MDClC and LGMD2Imay be 
allelic disorders. To test this hypothesis we collected 
25 LGMD families, including 14 that were consistent with 
links to the LGMD2I locus. Mutation analysis of the FKRP 
gene identified mutations in 17 families. In patients where 
muscle was available, a secondary larninin a.2 deficiency and a 
variable reduction in a-dystroglycan expression were 
observed. · 
RESULTS 
Mutation screening of the FKRP gene in LGMD21 
Sequence analysis ·of the FKRP coding ~egion identified 
mutations in individuals from 17 families, whose clinical 
features are summarized in Table 1 and mutations in Table 2. 
Unexpectedly, 15 families had an identical - C826A 
(Leu276lleu) mutation, of which five were homozygous for the 
mutation and the remainder were compound heterozygotes. 
None of the homozygous individuals was the offspring of 
consanguineous marriages. In the 10 families heterozygous for 
the C826A mutation we were able to identify the second allelic 
mutation in four cases. These were two missense mutations in 
families 7 and 9 (C934T and C947G), one nonsense mutation 
due to a 4 nt duplication in family 2 (390insTACC) and a 12 nt 
in-frame deletion (426de112) in family 10. In two families 
without the C826A mutation, we identified a homozygous 
G I 0 16A missense mutation in family 1, a consanguineous 
family, and a C427 A heterozygous missense mutation in 
family 11. Since the C826A mutation was present in a large 
number of families, we took advantage of the loss of a Bfai 
_ restriction site induced by the chan3e·(Materials and Methods; 
Fig. 1) to rule out this to be a polymorphism. On screening 
138 
controls, orily one heterozygous individual was identified out 
of a total of 200 control chromosomes. We considered these 
mutations to be pathogenic since they were not present in at 
least 100 control chromosomes and segregated with the disease 
in an autosomal recessive fashion. 
In eight cases we did riot observe any changes in the FKRP 
coding sequence. Four of these individuals came from geneti-
cally informative families that were compatible with linkage to 
the FKRP locus. The other four were isolated cases. 
Haplotype analysis .of families with the C826A mutation 
We used markers D 19S219 and D 19S606 to haplotype families 
harbouring the C826A mutation; since radiation hybrid 
-mapping suggested these were the closest markers flanking 
FKRP in the Genethon database. The order of markers is 
centromere-DJ9S219-FKRP-Dl9S606-telomere. The 
interval between the markers is 3 cM according to_ the Gene-
than map. Sequence data for this region of the genome puts 
D 19S606 as the closest marker, no more the 500 kb down-
stream of the F KRP gene. In 10 families haplotyping _was 
possible to check forlinkage disequilibrium with the C826A 
mutation. Amongst the families tested, there was _not a 
conserved haplotype (Fig. 2). However, marker DI9S606, the 
most closely linked marker to FKRP, identified two alleles at a 
higher than expected frequency. Allele 2 was found in five 
haplotypes and allele 5 in four haplotypes (compared to a 
frequency of 0.036 for allele 2 and 0.018 for allele 5 in the 
CEPH database). 
Immunohistochemistry and western_ blotanalysis 
The histological changes were characteristic of a muscular 
dystrophy in all patients. The expression of all proteins regu-
larly screened for in the biopsies of patients with muscular 
dystrophy were normal. These included dystrophin, o:-, ~-. y-
sarcoglycans, caveolin, dysferlin, emerin, lamin A/C and 
calpain 3 (data not shown). Immunocytochemical analysis of 
laminin a2 using antibodies against both the 80 and 300 kDa 
fragments was reduced in· several patients with a more severe 
phenotype (Fig. 3; Table 1 ), wh-ereas it was hormal in the 
remaining patients with the exception of few scattered fibres 
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Figure 3.lrnmunocytochemical .localization of a.-dystroglycan (A-C), ~-dystr.oglycan -~FJ:'llld 1aiD.inin:·a.2 (300 kDa) (G-1) in control muscle (A, D and G), 
family 5 (B, E and H) and family 15 (C, F and I). · 
(data not shown). Since a.-dystroglycan is a heavily glyco-
sylated protein, we used two antibodies, VlA4-1 (Upstate 
Biotechnology) raised against an unknown epitope and a sheep 
polyclonal antibody, directed towards the core · protein. Both 
antibodies clearly delineate individual muscle fibres with no 
apparent d~erences between fibre types in control muscle. In 
10 patients with LGMD2I whose musclt(.,was· available: to ' 
study, a.-dystroglycan expression was found tobe abnormal .. 
(Table 1). This was more marked using the VlA4-1 antibody 
than with the antibody to the core protein in (Fig.-5i\):' the 
apparent reduction in a.-dystroglycan was more marked than 
laminin ·a.2 (Fig. 3B). The pattern of P-dystroglycan labelling 
was normal, including those fibres in which a.-dystroglycan 
was reduced. 
Western blot analysis using an antibody that recognized the 
80 kDa·merosin fragment revealed an absence or near-absence 
of labelling in family 15 (Fig. 4) . This is identical to previous 
observations in this family, who along with families 13, 14 and 
16, were reported as being affected by an 'adul t merosino-
pathy ' (18). The molecular mass of residual laminin a.2 was 
normal, as was the expression of other proteins studied 
(Fig. 4). The virtual absence oflam·inin a.2 on western blot was 
in marked contrast with the immunocytochemical analyses , 
where no reduction in its expression w evident. 
139 
DISCUSSION 
In this work mutations in the FKRP gene were identified in 
affected individuals from 17 families with LGMD2I. We orig-
inally demonstrated that mutations in this gene cause a severe 
form of CMD, MDClC (IS). The patients in this work had a 
vari~ble phenotypf(, though a}.i wer~ I~ss sey_er~ than .MD Cl C 
"wh~re-·:~ p·aticmts ·'never' ··a:eqniri?d :·'mdepe!l~.en.V:ambUlatiOp.F 
Patients ·ai the sev6re end of the. spectrUm presented within the' 
first 2 years of life with hypotonia, del~yed motor miiestones 
and fo!J.owed by muscle hypertrophy (mostly in the legs, but 
also involving the tongue in several cases). These patients 
never acquired the ability to run or hop and followed a Duch-
enne-like disease course, with loss of independent ambulation 
in the early teens, followed by the development of cardiomy-
opathy. The remaining patients had milder phenotypes and are 
similar to those described in a large Tunisian family featured in 
the original description of LGMD2I (1 8). These patients were 
characterized by a later disease onset and a relatively benign 
course. Calf and to a lesser extent, thigh, brachioradialis and 
tongue muscle hypertrophy were present in most patients. 
Muscle cramps following exercise were also relatively 
common; one case had spontaneous myoglobinuria. intelli-
gence and brain MRI were normal. Serum CK was grossly 
elevated in all patients (between 10 and 30 times normal 
values) and the h art was variably aH cted, a~ ature not previ-
c p c . 
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Dys -:=- - 400 
Dysf ~.~ ............._ 230 
Calpain 3- tee -~ 94 
Laminin- <;~''. - 80 
a2 
a.Sarc-.;. 50 
,BDyst- 43 
Calpain 3 
fragment 
MHC 
30 
igure 4. Multiplex western blot showing the marked reduction of the 80 kDa 
gment of the laminin a.2 chain in family 15 (P) relative to controls (C). 
tein loading of all samples was equivalent as shown by the staining of MHC 
n the gel after blotting. 
usly reported in LGMD2I. The range of phenotypic severity 
tie to FKRP mutations is surprisingly large and so far not 
bserved in other forms of muscular dystrophy. · 
The FKRP mutations identified in the LGMD2I families 
ere different from those seen in MDCIC. The most severe 
atient in this series was a consanguineous child from family 1 
ho was symptomatic in the first year of life and whose motor 
ilestones- were delayed. His phenotype was clearly inter-
ediate between MDC1C and LGMD2I. Fifteen families had 
identical C826A missense mutation. The five patients 
omoeygous. for this mutation had a relatively mild ph~type, 
hereas :contpmind heterozygotes for this · mutation·-.oo ·the · 
hole had a more severe phenotype. Linkage analysis failed to 
dentify a single founder haplotype associated with this 
utation. However, we did observe two rare alleles of 
19S606 that appeared to be in linkage disequilibrium with the 
utation, suggesting it may have arisen on a limited number of 
ccasions. Although we identified FKRP mutations in 17 fami-
. es, we were unable to find mutations in four families that 
ere consistent with linkage to this locus. In addition, we have 
'led to identify the second mutation in six of the 10 
ompound heterozygotes for the C826A mutation. This 
ongly suggests that mutations exist outside the FKRP coding 
gion in at least some of these families and analysis of these 
gions is presently under way. 
Patients at the severe end of the LGMD2I spectrum showed 
mild deficiency of laminin a.2 at the immunohistochemical 
vel. Patients wi th milder phenotype had n mml expres ion 
laminin a.2 on immunohistochemistry, but in four patients 
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western blot analysis identified a severe deficiency or total 
absence of this . protein. These four families have been 
described previously by Bushby et al. (19). The discrepancy 
between the immunocytochemical and western blot analysis 
suggests that mutations in FKRP result in the altered 
processing, epitope masking or abnormal folding of the 
laminin a.2 polypeptide chain. The expression of a.-dystro-
glycan, but not ~-dystroglycan, was abnormal in all muscle 
biopsies of LGMD21 patients available for study, an identical 
finding to MDClC. a.- and ~-dystroglycans are derived from 
post-translational cleavage of a single precursor peptide (20). 
a.-Dystroglycan is a heavily glycosylated peripheral membrane 
protein that forms a link between the actin associated cytoskel-
eton and, via larninin u2, the extracellular matrix (21 ,22). 
Larninin a.2 binds binds to a carbohydrate moiety of a.-dystro-
glycan (23). The pattern of a.-dystroglycan glycosylation 
differs not only between tissues · but also within them, and 
different glycoforms may have different binding partners that 
mediates the function of a.-dystroglycan (23,24). Mutations in 
the FKRP gene appear to result in a selective deficiency of a.-
dystroglycan in skeletal muscle, since the-expression of other 
muscle . proteins was normaL This is most likely due to an 
altered pattern of glycosylation, which would be expected to 
affect the function of a.-dystroglycan and be integral to the 
pathology in these patients. Recent evidence to support this 
comes from the abnormal expression of a.-dystroglycan in both 
FCMD (14) and the myd mouse, in which the LARGE glyco-
syltransferase gene is mutated (25). The deficiency of u-
dystroglycan represents an important biochemical marker in 
these conditions and in our experience is more sensitive than a 
deficiency of laminin .a.2 expression. _ 
Mutations in the FKRP gene account_ for a significant 
proportion of our patients with muscular dystrophy whose 
severity varied from a severe, congenital form characterized by 
inability to walk and early death (MDC1 C), to a much milder 
form where patients are still ambulant in the fifth decade of life 
(1.GMD21). In our experience LGMD21 accounts for a large 
proportion of patients who have been previously excluded 
from other LGMD disease loci. 
Most patients with a relatively mild disease course had a 
C826A mutation. As this mutation was mostly observed within 
two haplotypes, it is tinlikely that it has arisen \ndependently 
· on 'multiple independent events. It may be there is some 
unknown selection pressure for the maintenance of this 
mutation within the population. 
MATERIALS AND METHODS 
Patients 
Twenty-five families were studied after informed consent and 
approval of the local ethic committees. We have divided the 
case histories in two groups, depending on disease severity. 
Clinical information is summarized in Table 1. 
Patients with a severe phenotype (families 1-5) 
In five families the clinical features were clearly more severe 
than in the remaining cases with a typical LGMD2I phenotype, 
with onset of ymptoms before the age of~ years. Despite the 
overlap with MDClC, the disease course was significantly 
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milder when compared to this form of CMD, and resembled 
Duchenne muscular dystrophy in several aspects. 
The clinical features in these five families were character-
ized by delay in early motor milestones, waddling gait, diffi-
culties in running, mild facial weakness, calf and, in a few 
cases, tongue hypertrophy and Achilles tendon contractures. 
Intelligence and brain MRI were invariably normal whereas 
serum CK was markedly elevated (ranging from I 000 to 3160 
IU/l, normal value < 190). Spontaneous bouts of myoglob-
inuria were observed in one case. · 
Three cases lost the ability to walk before the age of 14; 
evidence of cardiac involvement was present in four of these 
children. Additional features noticed in some families were 
soft and hyperextensible skin. 
Families with a mild phenotype (6-17) 
The remaining 12 families belonged to this group. Four of 
these families have been describedin the past (19). There were 
a total of 16 affected individuals; all families were non-consan-
guineous. Early motor milestones were normal in each case. 
Onset of symptoms was in the first decade of life in one patient 
who complained of calf cramps aged 3 and enlargement of the 
calves. In the remaining patients onset of symptoms was in the 
second or third decade of life. Weakness affected the lower 
girdle causing waddling gait. With the exception of one 
patient, who deteriorated following an accident, making her . 
wheelchair dependent, progression was not severe with all 
atients remaining ambulant. Mild facial and neck flexion 
eakness ·was present in most patients. Calf and, less 
ommonly, brachioradialis hypertrophy were observed. 
oximal muscles in the lower and upper limbs were weaker 
an distal muscles. There was a mild reduction in lateral 
exion arid rotation of the neck in several patients but 
therwise no significant contractures. Serum CK was 
arkedly elevated in all patients (1545-3696 IV/I, normal 
alue < 140 IV/I). Cardiac involvement, in the form of 
duction of left ventricular function, was noticed in three 
amilies. Cardiac involvement was also noticed in patients 
ith MDClC (15). 
inkage and haplotype analysis 
blood using standard 
rocedures after obtaining informed consent. Markers 
19S606 and D19S219, separated by 3 cM on the Genethon 
ap and spanning the FKRP locus, were used in initial linkage 
alysis. Primers amplifying these markers were purchased 
om Invitrogen, with the forward primer modified at the 5' end 
the addition of either a F AM or NED fluorescent label. PCR 
ducts were separated on a 5% denaturing gel (Amresco) in 
ABI 377A automated DNA sequencer (ABI) and analysed 
ing Genescan v3.01 and Genotyper v2.01 software. 
.,RP mutational analysis 
1.7 kb fragment containing FKRP exon 4 and the entire 
ding sequence was amplified from genomic DNA using 
vantage-GC Genomic Polymerase Mix (Clontech) and 
. 'mers FKRP-lF (AAAGGGAAITGAGAAAGAGC) ano 
-5 (GCTCACACAGAGCITCTCC). PCR products 
were separated by agarose gel electrophoresis, purified 
(Qiagen) and used for direct sequencing. Sequencing reactions 
were carried out using an ABI Prism BigDye Terminator Cycle 
Sequencing ldt (Applied Biosystems) and reverse primers 
FKRP-lR (GCAGGAAGGAGTCTACCAG), FKRP-2R 
(CCGAGAGGTTGAAGAGGT), FK.RP-3R (CTCCTCGTA-
GAGGTAGGC), FKRP-4R (CCTTCTCCCATACGAAGC) 
and FKRP-5R. 
The C826A mutation was further analysed by restriction 
enzyme analysis. A 900 bp DNA fragment was amplified using 
pirners FKRP 2F (CC~"' 1\GAGGTTGAAGAGGT) and FKRP 
4R and digested under t'be manufacturer's conditions with Bfal 
(New England Biolabs). RCR products were separated on 2% 
agarose gels. Wild-type DNA was cut into two fragments of 
500 and 400 bp, whereas pruducts harbouring the mutation, 
which introduced the loss of this Bfal site, remained uncut. 
Immunocytochemistry 
Unfixed frozen 8 j.i.m sections were incubated with monoclonal 
antibodies to ~~spectrin, laminin a2, aS, pi, yl (Chemicon), 
V1A4-1 (a monoclonal antibody raised against a-dystro-
glycan; Upstate Biotechnology), sheep polyclonal raised 
against a-dystroglycan. All primary antibodies were applied 
for 1 hand revealed with an appropriate biotinylated secondary 
antibody (Jackson ImmunoResearch Laboratories) for 30 min, 
followed by streptavidin congugated to Alexa 594 (Jackson 
ImmunoResearch Laboratories) for 15 min. All dilutions and 
washings were made in phosphate buffered saline. Sections 
were mounted in aqueous mountant and viewed with epifluo-
rescence using a Leica Aristoplan microscope. Control 
sections were labelled without primary antibodies, and all 
sections were compared with control samples from other 
neuromuscular disorders, and with normal muscle. 
Western blotting 
Muscle proteins were extracted in treatment buffer containing 
0~125 mil/1 Tris-HCLbuffer pH 6.4; 10% glycerol, 4% SDS, 
4 mol/l urea, 10% mercaptoethanol and 0.001% bromophenol 
blue (final pH of the treatrn~nt buffer· was 6.8). Soluble 
proteins were separated using the Mutiplex System of western 
blotting and then electrophoretically transferred onto nitro-
cellulose for 7 h as described previously (18). After blotting, 
the gels were fixed in 20% trichloroacetic acid and stained in 
0.115% Coomassie brilliant blue R250 in 25% ethanol/10% 
acetic acid and destained in 10% ethanol/1 0% acetic acid. The 
density of the myosin heavy-chain band on the dried, post-
blotted gel was used to indicate how much muscle protein had 
been loaded. For visualization of blotted proteins nitro-
cellulose strips were blocked in 5% milk powder in a pH 8 
buffer containing 10 mmol/l Tris-HCL, 0.15mol/l NaCl and 
0.05% Tween 20 (TBST). Blots were probed with antibodies 
to dystrophin [Dy8/6C5, calpain 3, a-sarcoglycan, P-dystro-
glycan (all available from Novocastra Laboratories) and 
laminin a2 chain (80 kDa fragment; Chemicon)] and visual-
ized using peroxidase-conjugated anti-mouse secondary anti-
bodY followed by exposure to fresl1Iy prepared 0.05% 
diaminobenzidine. 
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